WO2011072275A2 - Agents et méthodes de traitement de maladies ischémiques et d'autres maladies - Google Patents

Agents et méthodes de traitement de maladies ischémiques et d'autres maladies Download PDF

Info

Publication number
WO2011072275A2
WO2011072275A2 PCT/US2010/059976 US2010059976W WO2011072275A2 WO 2011072275 A2 WO2011072275 A2 WO 2011072275A2 US 2010059976 W US2010059976 W US 2010059976W WO 2011072275 A2 WO2011072275 A2 WO 2011072275A2
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
alkyl
trpm7
pharmaceutical composition
ring
Prior art date
Application number
PCT/US2010/059976
Other languages
English (en)
Other versions
WO2011072275A3 (fr
Inventor
Xiujun Sun
Michael Tymianski
Jonathan David Garman
Original Assignee
Nono, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nono, Inc. filed Critical Nono, Inc.
Priority to AU2010327936A priority Critical patent/AU2010327936B2/en
Priority to JP2012543324A priority patent/JP5848712B2/ja
Priority to CA2781888A priority patent/CA2781888C/fr
Priority to EP10836790.5A priority patent/EP2521724B1/fr
Publication of WO2011072275A2 publication Critical patent/WO2011072275A2/fr
Publication of WO2011072275A3 publication Critical patent/WO2011072275A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Definitions

  • the transient receptor potential channel TRPM7 is a member of the TRP superfamily of cation channels that comprises greater than 20 cation channels that play critical roles in varied processes within the body.
  • TRP channels are integral membrane proteins in which the ion-conducting pores are formed by six membrane-spanning helical segments that are similar to those of voltage-gated potassium channels and cyclic nucleotide-gated channels.
  • TRP channels are divided into three families based on their homology. The families are the short TRP channel family, the osm TRP family, and the long TRP family. Long TRP channels can be distinguished by their having particularly long extensions outside the channel segment. Long TRP channels are involved in critical control mechanisms regulating cell growth, differentiation and death ((Montell et al., 2002, Harteneck et al, 2000).
  • TRPM7 channel belongs to the long TRP family.
  • the human TRPM7 protein was first identified by Runnels et al (2001)) and was identified as a bifunctional protein with kinase and ion channel activities.
  • TRPM7 was identified as a Mg-ATP regulated cation channel required for cell viability.
  • Runnels et al. (2002) reported that , TRPM7 is a calcium-permeant ion channel.
  • TRPM7 kinase domain directly associates with the C2 domain of phospholipase C (PLC) and that 4,5-biphophate (PIP 2 ), the substrate of PLC, is a key regulator of TRPM7.
  • PLC phospholipase C
  • PIP 2 4,5-biphophate
  • the TRPM7 channel produces pronounced outward currents at nonphysio logical voltages ranging from +50 to +100 mV and small inward currents at negative potentials between -100 to -40 mV when expressed heterologously in mammalian cells (Jiang et al., 2005)
  • the basal activity of TRPM7 was originally
  • TRPM7 reported to be regulated by millimolar levels of intracellular mgATP and Mg . It is now recognized that the TRPM7 channel is unlikely to be gated by ATP (it was the Mg2+ in the MgATP that, when depleted, caused the channel to open). TRPM7 is activated by depletion of intracellular Mg 2+ , and is inhibited by high concentrations of Mg 2+ with an IC50 of about 0.6 mM (Nadler et al., supra, Jiang et al., supra). The TRPM7 channel is also known as the CHAK, CHAK1, LTRPC7, FLJ20117 or TRP-PLIK channel.
  • the TRPM7 channel is also activated by a reduction in extraellular divalent cation levels, especially Mg2+ and Va2+. More recently, the TRPM7 channel has been shown to be involved in ischemic CNS injury and anoxic neuronal cell death (Aarts et al., 2003; Aarts and Tymianski, 2005a, Aarts and Tymianski, 2005b).
  • AET antiexcitotoxic therapy
  • Aarts et al. (2003) have shown that in murine neurons subjected to prolonged oxygen glucose deprivation (OGD), AET unmasks a dominant death mechanism perpetuated by a Ca2+-permeable nonselective cation conductance (IOGD).
  • IOGD was activated by reactive oxygen/nitrogen species (ROS), and permitted neuronal Ca2+ overload and further ROS production despite AET.
  • ROS reactive oxygen/nitrogen species
  • TRPM7 suppression eliminated the need for AET to rescue anoxic neurons and permitted the survival of neurons previously destined to die from prolonged anoxia.
  • excitotoxicity may be is a subset of a greater overall anoxic cell death mechanism, in which TRPM7 channels play a key role.
  • Transient periods of brain ischemia are characterized by substantial decreases in extracellular Ca(2+) and Mg(2+) that mimic the initial condition of the Ca(2+) paradox.
  • Wei et al. (, 2007) have shown that In CAl hippocampal neurons, lowering extracellular divalents stimulates a nonselective cation current. They showed that this current resembles TRPM7 currents in several ways.
  • TRPM7 contributes to the mechanism by which hippocampal neurons "detect" reductions in extracellular divalents and provide a means by which TRPM7 contributes to neuronal death during transient brain ischemia.
  • the invention provides methods of screening for compounds that modulate the injurious effects of TRPM7 gene and protein activity on mammalian cells, classes and specific compounds that modulate the injurious effects of TRPM7 activity on mammalian cells, and methods of treating the injurious effects of TRPM7 activity and ischemic damage on mammalian cells.
  • the invention provides pharmaceutical compositions comprising a compound according to any of Formulae I to XIX, or any other compound or genera of compounds disclosed herein, or pharmaceutically acceptable salts of such compounds.
  • Preferred compounds are designated M5, M6, Ml 1, M 14 and M21.
  • Some compounds inhibit inhibit TRPM7-mediated cell death in mammalian cells by at least 50, 60, 70 or 80% relative to a control assay lacking the compound.
  • compositions In some pharmaceutical composition the compound or pharmaceutically acceptable salt thereof is at least 95 or 99% w/w pure of contaminants from its production. Some compositions further comprise a carrier acceptable for human administration. Some compositions contain a unit dose of the compound or
  • compositions are formulated for oral administration. Some such pharmaceutical composition are formulated as a pill or capsule. Some pharmaceutical compositions are formulated for patenteral administration. Some such pharmaceutical compositions are packaged in a vial containing a unit dose of the agent. Any of these pharmaceutical compositions can be used in prophylaxis of treatment of disease.
  • compositions or compounds or pharmaceutically acceptable salts thereof described in the application can be used in prophylaxis or treatment of ischemic disease, such as when the ischemia is cardiac, renal, retinal or CNS ischemia.
  • the pharmaceutical compositions, or compounds or pharmaceutically acceptable salts thereof described in the application can also be used for treating or prophylaxis of cancer, such as when the cancer is renal cancer, small lung cell cancer, nonsmall lung cell cancer, colon cancer, retinoblastoma, breast cancer, melanoma, adrenal carcinoma, cervical cancer, or osteosarcoma.
  • the invention further provides a method of prophylaxis or treatment of a damaging effect of ischemia in a mammalian subject, comprising administering to a mammal subject having or at risk of ischemia an effective regime of a pharmaceutical composition, compound or a pharmaceutically acceptable salt as specified above or herein.
  • the ischemia is cardiac, renal, retinal or CNS ischemia.
  • the invention further provides a method of prophylaxis or treatment of cancer in a mammalian subject, comprising administering to a mammal subject having a cancer or at risk of cancer an effective regime of a pharmaceutical composition, compound or a pharmaceutically acceptable salt thereof as specified above or herin, optionally wherein the cancer is renal cancer, small lung cell cancer, nonsmall lung cell cancer, colon cancer, retinoblastoma, breast cancer, melanoma, adrenal carcinoma, cervical cancer, or osteosarcoma.
  • the invention further provides a compound of formula V (compound M21 and related compounds) or a pharmaceutically acceptable salt thereof for use in treating or prophylaxis of ischemia, pain, glaucoma or cancer.
  • the invention further provides a compound of formula III (compound M6 and related compounds) or a pharmaceutically acceptable salt thereof for use in treating or prophylaxis of cancer.
  • the invention further provides a compound of formula IX (Ml 1 and related compounds) for use in treating or prophylaxis of ischemia or cancer.
  • the invention further provides a compound of formula XI (Ml 4 and related compounds) for use in treating or prophylaxis of ischemia or cancer.
  • the invention further provides a method of screening for an inhibitor of TRPM7, comprising activating TRPM7 in cells expressing TRMP7;contacting the cells with an agent; determining whether the agent inhibits death of the cells; and if the compound inhibits death of the cells, determining whether the agent inhibits an ion current through the TRPM7 channel; inhibition of an ion current indicating the agent is an inhibitor of TRPM7 channel.
  • the method further comprises determining whether the agent inhibits a damaging effect of ischemia in a cell or animal model of ischemic injury.
  • the invention further provides for use of host cells or progeny of the host cells.
  • the host cell is a eukaryote.
  • the host cell comprises an expression vector that comprises a murine TRPM7 polynucleotide in which the nucleotide sequence of the polynucleotide is operatively linked with a regulatory sequence that controls expression of the polynucleotide in a host cell or progeny of the host cell.
  • the invention provides a host cell comprising a murine TRPM7 polynucleotide, wherein the nucleotide sequence of the polynucleotide is operatively linked with a regulatory sequence that controls expression of the
  • polynucleotide in a host cell or progeny of the cell.
  • the nucleotide sequence of the polynucleotide can be operatively linked to the regulatory sequence in a sense or antisense orientation.
  • the invention further provides a method of screening bioactive agents comprising: a) providing a cell that expresses an inducible or constitutively expressed murine TRPM7 gene as described herein; b) inducing the expression of the TRPM7 protein if needed, c) activating the channel d) adding a bioactive agent candidate to the cell; and e) determining the effect of the bioactive agent candidate on the cellular injury produced by the expression product of the TRPM7 gene under said ionic environment.
  • the determining comprises comparing the level of cellular injury in the absence of the bioactive agent candidate to the level of injury in the presence of the bioactive agent candidate.
  • the determining comprises comparing the level of cellular injury in the presence of the bioactive agent candidate but in the absence of induction of the TRPM7 gene to the level of injury in the presence of the bioactive agent candidate also in the presence of induction of the TRPM7 gene.
  • the invention further provides a method of screening bioactive agents for modulating cellular injury as described herein, but in a robotic system intended to achieve high-throughput screening.
  • the invention further provides a method for screening for a bioactive agent that increases or decreases the activity of a TRPM7 channel, the method comprising: a) providing a cell that expresses an inducible or constitutively expressed murine TRPM7 gene as described herein; b) inducing the expression of the TRPM7 protein (if needed), c) loading the cell with a fluorescent ion indicator compound to which TRPM7 protein- containing ion channels are permeable d) activating the channel, e) adding a bioactive agent candidate to the cell; and f) determining the effect of the bioactive agent candidate on the fluorescence of the ion indicator in the cell under said ionic environment.
  • the determining comprises comparing the level of fluorescence in the absence of the bioactive agent candidate to the level of fluorescence in the presence of the bioactive agent candidate. In some methods, the determining comprises comparing the level of the fluorescence in the presence of the bioactive agent candidate but in the absence of induction of the TRPM7 gene to the level of fluorescnece in the presence of the bioactive agent candidate also in the presence of induction of the TRPM7 gene.
  • the invention further provides a method of screening bioactive agents for modulating the fluorescence of an ion indicator compound as described herein, but in a robotic system intended to achieve high-throughput screening.
  • the invention further provides a method for screening for a bioactive agent that modulates the monovalent or divalent cationic permeability of a channel comprising a TRPM7 protein comprising a) providing a recombinant cell comprising a recombinant nucleic acid encoding a TRPM7 protein and an inducible or constitutive promoter operably linked thereto; b) inducing the recombinant cell to express the TRPM7 protein and form a channel comprising the TRPM7 protein (if needed); c) contacting the recombinant cell with a candidate bioactive agent; d) activating the channel; and e) detecting modulation of TRPM7-mediated cellular injury.
  • the TRPM7- mediated cellular injury is increased by contacting the cell with the bioactive agent. In another aspect, the TRPM7-mediated cellular injury is decreased by contacting the cell with the bioactive agent. In another aspect, contacting the cell with the bioactive agent alters the fluorescence of an ion indicator compound loaded into the cell.
  • the invention further provides a method for screening for a bioactive agent that increases or decreases ion flux through a murine TRPM7 channel, the method comprising: a) contacting a candidate bioactive agent with a TRPM7 protein wherein the TRPM7 protein forms a TRPM7 channel; and b) determining the functional effect of the bioactive agent on the TRPM7 channel-mediated ion flux as determined by a fluorescent ion indicator.
  • the determining step comprising comparing the indicators' fluorescence in the absence of the bioactive agent to the indicator's fluorescence in the presence of the bioactive agent.
  • the invention further provides an expression cassette comprising a
  • the promoter is heterologous to the coding sequence.
  • the promoter is a tissue specific promoter.
  • the promoter is an inducible promoter.
  • the viral vector is selected from the group consisting of a retroviral vector, an adenoviral vector, and adeno-associated viral vector, a vaccinia viral vector, and a herpesviral vector.
  • Some such expression cassette further comprises a polyadenylation signal.
  • the invention further provides a cell comprising an expression cassette comprising a polynucleotide encoding a murine TRPM7 polypeptide, wherein said polynucleotide is under the control of a promoter operable in eukaryotic cells, said promoter being heterologous to said polynucleotide.
  • the invention further provides a method of screening for a modulator of ischemic injury, said method comprising: contacting a recombinant cell or cell line that expresses the inducible or transiently expressed TRPM7 gene with a test compound under conditions that activate TRPM7 channel activity; and detecting an increase or a decrease in the amount of cell death.
  • the invention further provides a method of screening for a modulator of ischemic injury, said method comprising: producing a stroke in a rat or mouse, administering to said murine an effective amount of said modulator, and determining the impact on the size of the stroke.
  • the determining step comprising determining the area of ischemic tissue in a standardized section of the murine brain.
  • the determining step comprising determining the volume of ischemic tissue in the murine brain.
  • the determining comprises comparing the size of the stroke in the absence of the bioactive agent candidate to the size of the stroke in the presence of the bioactive agent candidate.
  • Analogous assays can be performed in a mouse or rat model of myocardial infarction or glaucoma or any of the animal models described herein.
  • Figures 1, 2A, 2B, 3A, 3A, 4A, 4B, 5A, 5B, 6, 7A, 7B, 8, 9 and 10A, 10B Compounds from Lopac and Prestwick libraries
  • FIG. 11-16 M1-M30 structures
  • Figure 17 Cultured hippocampal neurons demonstrate graded responses to reductions in extracellular divalents.
  • A-D Graded increases in action potential firing frequency are detected when sequentially applying solutions containing 1.3 mM Ca2+ and 0.9 mM Mg2+ (standard solution) (A), 0.2 mM Ca2+ and 0.9mMMg2+ (low Ca2+) (B), 0 mMCa2+ and 0.9mMMg2+ (Ca2+-free) (C), or 0.2 mM Ca2+ and 0.2 mM Mg2+ (low divalent) (D).
  • Figure 18 Effect of Tet Induction and the indicated different buffer conditions on cell death as measured by propidium iodide (PI) fluorescence in TRPM7-expressing HEK293 cells at the indicated times in an assay performed in a 24 well plate format.
  • PI propidium iodide
  • Figure 19 Effect of Tet Induction and the indicated different buffer conditions on cell death as measured by propidium iodide (PI) fluorescence in TRPM7-expressing HEK293 cells at the indicated times in an assay performed in a 96 well plate format.
  • PI propidium iodide
  • Figure 20 Effect of Tet Induction and the indicated different buffer conditions on cell death as measured by propidium iodide (PI) fluorescence in TRPM7-expressing HEK293 cells at the indicated times in an assay performed in a 384 well plate format.
  • PI propidium iodide
  • Figure 21 Effect of adding a candidate test compound at the same time as Tet induction on the expression of FLAG-TRPM7 in HEK293 cells.
  • Figure 22 Scatterplots of B-scores obtained by screening the Maybridge compound library for the ability of the test compounds to reduce TRPM7-mediated cell death in stably -transfected, Tet-inducible HEK293 cells.
  • FIG. 23 TRPM7 expression in rat tissues, mouse tissues and H9c2 cardiac myocytes. RNA from rat tissues, mouse tissues, and H9c2 cells was reverse-transcribed and PCR carried out using rat- and mouse- TRPM7-specific primers. TRPM7 expression was visualized as a 530bp band on a 1% agarose gel. D-actin served as a loading control.
  • Figure 24 Immunocytochemical analysis of TRPM7 immunofluorescence in H9c2 cells. The cells were stained with the indicated primary and secondary antibodies, and viewed with a confocal microscope at the indicated magnification.
  • Figure 25 Anoxic cell death in H9c2 cells. Exposure of H9c2 cells to 16hr anoxia (5% C02, 10% H2, 85% N2) and 2hr recovery resulted in an approximately 4- fold increase in cell death as measured by PI uptake. Normoxic cultures were maintained at 37 degrees C in a humidified 5% C02 atmosphere. Results are presented as mean +/- SEM from four experiments. Data are analyzed as the fraction of dead cell (A), or as the amount of death relative to controls (B).
  • Figure 26 Inhibition of anoxic (6hr anoxia + 2hr recovery) cell death in H9c2 cells following exposure to the indicated quantity of gadolinium in HBSS buffer.
  • Figure 27 Schematic of Flag-TRPM7/pBluescript KS II.
  • A Schematic of the Flag-TRPM7/pBluescript construct depicting sites of EcoRI, Kpnl, and Spel digest. Abbreviations: TRPM7, TRPM7 cDNA; Flag, Flag tag sequence; rep, promotes replication of the plasmid; Amp, ampicillin resistance gene.
  • B Restriction enzyme digest with EcoRI produced 3 fragments corresponding to a 3' ⁇ 5' direction of insert in the pBluescript vector (lane 3), length in bps: 3838, 3200, 1592. Lane 1 : lkb DNA ladder; lane 2: control, undigested plasmid.
  • Figure 28 Schematic of Flag-TRPM7/pTracer-CMV2.
  • A Schematic of the Flag-TRPM7/pTracer eGFP(+) construct depicting the expected sites of BamHI, EcoRI, EcoRV, and Pmel digest. The region encompassed by the NgoMIV restriction sites are absent from the eGFP(-) construct.
  • B Restriction digest of the eGFP(+) construct.
  • Lane 1 lkb DNA ladder
  • lane 2 control, undigested plasmid. Fragment lengths, in bps, for EcoRV: 11449; EcoRI: 6657, 3200, 1592; Pmel: 5769, 5680; BamHI: 5857, 4000, 1592.
  • FIGURE 29 Transient transfection of HEK-293T cells with the full-length TRPM7 construct.
  • A Representative images of eGFP and Hoechst fluorescence 48 hours post-transfection. Green: eGFP expression; blue: Hoechst.
  • B Representative phase images of untransfected cells and of cells transfected with the
  • FIGURE 30 TRPM7 expression increases calcium uptake induced by chemical anoxia (1 hour). Untransfected cells and cells expressing the full-length TRPM7 channel were exposed to NaCN treatment and calcium uptake monitored by fluo-3.
  • A Bars represent mean ⁇ sem of 4-5 separate experiments. * indicates significant difference from untransfected controls by Student's t test, p ⁇ 0.05; ** p ⁇ 0.01.
  • B Fitted dose-response curves of calcium uptake induced by NaCN treatment at 1 hour. Symbols represent mean ⁇ sem of 4-5 separate experiments.
  • FIGURE 31 TRPM7 expression increases calcium uptake induced by chemical anoxia (2 hours). Untransfected cells and cells expressing the full-length TRPM7 channel were exposed to NaCN treatment and uptake monitored by fluo-3.
  • A Bars represent mean ⁇ sem of 4-5 separate experiments. * indicates significant difference from untransfected controls by Student's t test, p ⁇ 0.05; ** p ⁇ 0.01.
  • B Fitted dose- response curves of calcium uptake induced by NaCN treatment at 2 hours. Symbols represent mean ⁇ sem of 4-5 separate experiments.
  • Figure 32 Expression of full-length TRPM7 increases cell death induced by chemical anoxia. Cells were treated with NaCN for 2 hours and cell death assessed by PI uptake. PI uptake values are normalized to Fmax by the addition of 0.05% Triton X-100. Bars represent mean ⁇ sem of 4-5 separate experiments. * indicates significant difference from untransfected controls, ANOVA followed by post hoc Holm-Sidak pairwise multiple comparisons, p ⁇ 0.05; ** p ⁇ 0.01. # indicates significant difference from TRPM7-transfected cells, p ⁇ 0.05; ## p ⁇ 0.01.
  • Figure 33 Drug M21 reduces the damage to the heart in an in vivo mouse model of myocardial infarction.
  • Figure 34 Characterization of TRPm7-like currents in HEK293 cells.
  • Figure 35 Effect of Compound M5 on TRPm7 Currents, % of control, and cell survival following tet-induced TRPm7 in HEK293 cells.
  • Figure 36 Effect of Compound M6 on TRPm7 Currents, % of control, and cell survival following tet-induced TRPm7 in HEK293 cells.
  • Figure 37 Effect of Compound M7 on TRPm7 Currents, % of control, and cell survival following tet-induced TRPm7 in HEK293 cells.
  • Figure 38 Effect of Compound Ml 1 on TRPm7 Currents, % of control, and cell survival following tet-induced TRPm7 in HEK293 cells.
  • Figure 39 Effect of Compound Ml 4 on TRPm7 Currents, % of control, and cell survival following tet-induced TRPm7 in HEK293 cells.
  • Figure 40 Effect of Compound M21 on TRPm7 Currents, % of control, and cell survival following tet-induced TRPm7 in HEK293 cells.
  • Figure 41 Compounds M5, Mi l and M21 are able to reduce retinal ischemia in rat retinal explants subjected to oxygen-glucose deprivation (OGD).
  • OGD oxygen-glucose deprivation
  • Figure 42 Compounds M5, Mi l and M21 can reduce retinal cell death in rat retinal explants that have been dissociated and subjected to oxygen-glucose deprivation (OGD).
  • OGD oxygen-glucose deprivation
  • Figure 43 Percent cell death in dissociated mixed rat retinal cultures subjected to OGD in the presence or absence of different compounds.
  • Figure 44 Compounds M5 and M21 significantly reduce the amount of cell death following OGD in the rat ventricular myoblast cell line H9c2
  • Figure 45 Optimization of Screening buffer conditions for TRPm7 expression under a tet on/off expression system in HEK293 cells.
  • Figure 46 Optimization of of the duration of tet induction of TRPm7 in HEK293 cells.
  • Figure 47 Titrations of compounds identified in chemical screens that inhibit TRPm7 -induced cell death.
  • Figure 48 Titrations of compounds identified in chemical screens that inhibit
  • Figure 50 Titrations of compounds identified in chemical screens that inhibit
  • Figure 51 Titrations of compounds identified in chemical screens that inhibit
  • Figure 52 Titrations of compounds identified in chemical screens that inhibit TRPm7 -induced cell death.
  • Figure 54 Titrations of compounds identified in chemical screens that inhibit
  • Figure 55 Effect of compounds on PI uptake in Primary cultured mouse cortical cells 20h after OGD.
  • Figure 56 Effect of compounds on PI uptake in Primary cultured mouse cortical cells 20h after OGD.
  • Figure 57 Effect of compounds on PI uptake in Primary cultured mouse cortical cells 20h after OGD.
  • Figure 58 Effect of compounds on PI uptake in Primary cultured mouse cortical cells 20h after OGD.
  • Figure 59 Effect of compounds on PI uptake in Primary cultured mouse cortical cells 20h after OGD.
  • Figure 60 Toxicity of compounds applied to mouse primary cultured cortical cells for 24 hours.
  • Figure 61 Toxicity of compounds applied to mouse primary cultured cortical cells for 24 hours.
  • Figure 62 Toxicity of compounds applied to mouse primary cultured cortical cells for 4 hours.
  • Figure 63 Toxicity of compounds applied to mouse primary cultured cortical cells for 4 hours.
  • Figure. 64 Scheme for high throughput screening.
  • Figure 65 Top portion: Effect of Compounds M6 and M21 on SRB (total protein) and MTT (cell viability) of Y79 retinoblastoma cell line.
  • Bottom state of Y79 cells treated for 72 hours with M21 (top row, from left to right: untreated, 5 micromolar M21, 7.5 micromolar M21 and 10 micromolar M21) and M6 (bottom row, from left to right: 1 micromolar M6, 2.5 micromolar M6, 5 micromolar M6 and 7.5 micromolar M6).
  • Figure 66 Effect of Compound M6 on B16F1 (melanoma) cell proliferation and growth after 72 hours of treatment.
  • Figure 67 Effect of Compound M6, M7 and Ml 1 on MCF-7 (breast) cell growth after 72 hours of treatment.
  • Figure 68 M21 reduces formalin-induced pain in experimental animals.
  • FIG. 69 TRPM7 inhibitors protect against death induced by Oxygen- Glucose Deprivation (OGD) in primary mouse cultured cortical cells. A) M21; B) M5; C) M6.
  • OGD Oxygen- Glucose Deprivation
  • Figure 70 TRPM7 inhibitors protect against death induced by Oxygen- Glucose Deprivation (OGD) in mouse AML 12 hepatocytes.
  • OGD Oxygen- Glucose Deprivation
  • Figure 71 TRPM7 inhibitors protect against death induced by Oxygen- Glucose Deprivation (OGD) in H9c2 cardiomyocytes. A) M21; B) M5; C)M6; D)M11.
  • Figure 72 TRPM7 inhibitors protect against death induced by Oxygen-Glucose Deprivation (OGD) in H9c2 cardiomyocytes when given before or during the OGD. A) M5 during OGD; B) M5 prior to OGD; C) M21 during OGD
  • Figure 73 A) TRPM7 reduces infarct volumes following LAD occlusion of rodent hearts. B) Representative TUNEL staining (red) in a heart cross section from vehicle and M21 treated mice. C) M21 significantly reduces dead cells following LAD restriction of the heart.
  • Figure 74 Effect of TRPM7 inhibitor on cell death.
  • B) TRPM7 inhibitors reduce cell death following 1 hr OGD in retinal explants.
  • Figure 75 M21 reduces retinal cell death in a rat model of acute glaucoma.
  • Figure 76 M6 reduces cell proliferation of retinoblastoma cells in culture by the MTT assay.
  • Figure 77 Effect of TRPM7 inhibitors on Y79 retinoblastoma cells cultured on retinal explants.
  • A) M6 reduces the number of viable Y79 cells on retinal explants.
  • B) M6 reduces the ability of Y79 retinoblastoma cells to migrate away from the retina in cultured explants.
  • Figure 78 M6 reduces the ability of Weri retinoblastoma cells to migrate away from the retina in cultured explants.
  • TRPM7 inhibitors reduce proliferation of cancer cell lines.
  • A) M7 reduces proliferation of HeLa cervical cancer cells.
  • B) M7 reduces proliferation of SW13 adrenal carcinoma cells.
  • C) M6 reduces proliferation of HeLa cervical cancer cells.
  • D) M6 reduces proliferation of SW13 adrenal carcinoma cells.
  • Figure 80 TRPM7 inhibitors M5 , M6 and M 11 inhibit proliferation of MCF-7 and MDA-MB231 breast cancer cells.
  • Figure 81 TRPM7 inhibitors M5 , M6 and M 11 inhibit proliferation of B 16F 1 and B16F10 melanoma cells.
  • Figure 82 TRPM7 inhibitors M5, M6, M7 and Mi l do not show toxicity on NIH3T3 fibroblast cells at concentrations that reduce proliferation of cancerous cells.
  • Figure 84 siRNA knockdown of TRPM7 in mouse B 16F 1 and B 16F 10 melanoma cell lines reduces proliferation by MTT and SRB assays.
  • Figure 85 M6 is able to slow tumor formation in an in vivo murine model of cancer.
  • the present invention provides, inter alia, modulators (sometimes referred to as compounds or agents) and methods of screening for other modulators (e.g., activators, inhibitors, stimulators, enhancers, agonists, and antagonists) of TRPM7 proteins.
  • modulators sometimes referred to as compounds or agents
  • other modulators e.g., activators, inhibitors, stimulators, enhancers, agonists, and antagonists
  • Such modulators can be used in the prophylactic or therapeutic treatment of ischemic and cytodegenerative diseases and conditions, including neurological diseases and conditions, such as stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, dementia, epilepsy, spinocerebellar ataxia, spinal and bulbar muscular dystrophy, dentatorubropallidoluysian atrophy, brain injury, spinal cord injuries, prion-based diseases, and other traumatic, ischemic or neurodegenerative nervous system injuries.
  • neurological diseases and conditions such as stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, dementia, epilepsy, spinocerebellar ataxia, spinal and bulbar muscular dystrophy, dentatorubropallidoluysian atrophy, brain injury, spinal cord injuries, prion-based diseases, and other traumatic, ischemic or neurodegenerative nervous system injuries.
  • modulators can also be used in the prophylactic or therapeutic treatment of non-neurological diseases, including ischemic and degenerative disorders and conditions of other tissues, such as those of the CNS, brain, heart, liver, kidneys, muscles, retina, skin, intestines, pancreas, gall bladder, thyroid, thymus, spleen, bone, cartilage, joints, lungs, diaphragm, adrenal glands, salivary and lacrimal glands, blood vessels, and cells of endodermal, mesodermal and ectodermal origin origin.
  • Such modulators can also be used in the prophylactic or therapeutic treatment of ocular disorders including macular degeneration, diabetic retinopathy, glaucoma, ischemic retinopathy.
  • modulators can further be used in the prophylactic or therapeutic treatment of cancer and other proliferative disorders, including breast cancer, retinoblastoma, head and neck cancers, gastric cancer, adrenal cancer, cervical cancer, osteosarcoma, colon cancer, renal cancer, lung cancer including small or non-small cell lung cancer, melanoma, leukemia and lymphoma.
  • the modulators can also be used to for prophylaxis or therapeutic treatment of pain.
  • the modulators can also be used to preserve or enhance memory, in the prophylaxis or therapeutic treatment of
  • hypertension hypertension, autoimmune disorders, arrhythmia, depressive distorders, stress disorders or immune disorders.
  • TRPM7 includes reference to human and/or murine TRPM& proteins.
  • Murine TRPM7 protein refers to an amino acid sequence that has at least 80%), at least 90%>, at least 95%>, preferably at least 99%> amino acid sequence identity, including at least 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or at least 99.9%), identity to an amino acid sequence encoded by a murine TRPM7 nucleic acid, e.g., a murine TRPM7 protein of Swiss-Prot Q923 Jl .
  • Nucleic acid encoding murine TRPM7 protein or "TRPM7 gene” or “TRPM7 nucleic acid” refers to a nucleic acid sequence that has at least 96% nucleic acid sequence identity, or at least 90%, 95%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or at least 99.9%, to a murine TRPM7 nucleic acid as shown in e.g., EMBL AY032951, their complements, or conservatively modified variants thereof.
  • a murine TRPM7 polynucleotide or polypeptide sequence can be naturally occurring or non-naturally occurring. It can be isolated from murine or synthetically constructed.
  • An "expression vector” is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell.
  • the expression vector can be part of a plasmid, virus, or nucleic acid fragment.
  • the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.
  • TRPM7 gene, TRPM7 protein or TRPM7-mediated cellular injury includes the determination of any parameter that is indirectly or directly under the influence of the TRPM7 gene or protein. It includes changes in ion flux and membrane potential, changes in ligand binding, changes in gene expression, changes in the fluorescence of ion indicator molecules, changes in cellular viability markers, changes in cellular integrity markers, changes in cellular metabolism markers, and changes in the quantity or function of ischemic tissue in a tissue preparation or in a whole animal. "Functional effects” also means all physiological and pathological effects such as increases or decreases in cell death following administration of a test compound.
  • determining the functional effect refers to determining the functional effect of a compound on a physiological or pathological process mediated by TRPM7 gene or protein. Such functional effects can be measured by any known means, e.g., cell death assays, cell viability assays, ion-sensitive fluorescent probes, electrophysiological techniques, and animal models of disease, and the like.
  • TRPM7 activity refers to one or more of: TRPM7 gene function, TRPM7 protein expression, TRPM7 protein activity as measured by electrophysiological measurements of ion channel activity, TRPM7 protein activity as measured by fluorescent ion indicators, and TRPM7 protein activity as measured using assays of cell metabolism or cell death or cell survival.
  • modulation refers to both upregulation, (i.e., activation or stimulation) for example by agonizing, and downregulation (i.e., inhibition or suppression) for example by antagonizing, TRPM7 activity as measured using the assays described herein.
  • An inhibitor or agonist may cause partial or complete modulation of binding.
  • TRPM7 activity sometimes referred to as agents or compounds of TRPM7 activity, TRPM7 genes and their gene products in cells also refer to inhibitory or activating molecules identified using assays for TRPM7 activity.
  • Inhibitors are compounds that decrease, block, prevent, delay activation, inactivate, desensitize, or down regulate the TRPM7 activity.
  • Activators are compounds that increase, open, activate, facilitate, enhance activation, sensitize or up regulate the TRPM7 activity.
  • Such assays for inhibitors and activators include e.g., expressing TRPM7 in cells or cell membranes and then inferring the flux of ions through the use of fluorescent ion indicators, or through measuring cell survival or cell death, after contacting a cell expressing TRPM7 with a putative modulator of TRPM7 activity.
  • samples or assays comprising a TRPM7 protein are treated with a potential activator or inhibitor and are compared to control samples without the activator inhibitor.
  • Control samples (untreated with inhibitors) are assigned a relative TRPM7 activity value of 100%. Inhibition of TRPM7 is achieved when the TRPM7 activity value relative to the control is about 90% or less, optionally about 80% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less; or 25-0%.
  • TRPM7 activity value relative to the control is about 110%, optionally 120%, 130%, 140%, 150% or more, 200-500% or more, 1000- 3000% or more.
  • TRPM7 inhibitor used interchangeably with “TRPM7 competitive inhibitor,” also referred to as a compound or agent, means that the subject compound reduces TRPM7 activity by at least 20%, e.g., at least 30%, at least 40%, at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, up to about 99% or
  • agents of interest are those which exhibit IC50 values in a particular assay in the range of about 1 mM or less.
  • Compounds that exhibit lower IC50s for example, have values in the range of about 250 ⁇ , 100 ⁇ , 50 ⁇ , 25 ⁇ , 10 ⁇ , 5 ⁇ , 2 ⁇ , 1 ⁇ , 500 ⁇ , 250 ⁇ , 100 ⁇ , 50 ⁇ , 25 ⁇ , 10 ⁇ , 5 ⁇ , 1 ⁇ , or even lower, and compounds with these attributes are presently preferred.
  • analog is used herein to refer to a small molecule that structurally resembles a molecule of interest but which has been modified in a targeted and controlled manner, by replacing a specific substituent of the reference molecule with an alternate substituent. Compared to the starting molecule, an analog may exhibit the same, similar, or improved utility in modulating a TRPM7 activity. Synthesis and screening of analogs, to identify variants of known compounds having improved traits (such as higher binding affinity, or higher selectivity of binding to a target and lower activity levels to non-target molecules) is an approach that is well known in pharmaceutical chemistry.
  • contacting has its normal meaning and refers to bringing two or more agents into contact, e.g., by combining the two or more agents (e.g., two proteins, a protein and a small molecule, etc.). Contacting can occur in vitro, in situ or in vivo.
  • agents e.g., two proteins, a protein and a small molecule, etc.
  • Recombinant when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified.
  • recombinant cells express genes that are not found within the native (non- recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.
  • a “promoter” is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid.
  • a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element.
  • a promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription.
  • a "constitutive" promoter is a promoter that is active under most environmental and developmental conditions.
  • An “inducible” promoter is a promoter that is active under environmental or developmental regulation.
  • operably linked refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.
  • a nucleic acid expression control sequence such as a promoter, or array of transcription factor binding sites
  • Recombinant host cell refers to a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell” as used herein.
  • a host cell is any cell suitable for expression of subject polypeptide-encoding nucleic acid.
  • an animal host cell line examples of which are as follows: monkey kidney cells (COS cells), monkey kidney CVI cells transformed by SV40 (COS- 7, ATCC CRL 165 1); human embryonic kidney cells (HEK-293); HEK-293T cells; baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary-cells (CHO); mouse Sertoli cells (TM4); monkey kidney cells (CVI ATCC CCL 70); african green monkey kidney cells (VERO-76, ATCC CRL- 1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL 51); TRI cells; NIH/3T3 cells (ATCC CRL- 1658); and mouse L cells (ATCC
  • a monovalent cation indicator refers to a molecule that is readily permeable to a cell membrane or otherwise amenable to transport into a cell e.g., via liposomes, etc., and upon entering a cell, exhibits a fluorescence signal, or other detectable signal, that is either enhanced or quenched upon contact with a monovalent cation.
  • monovalent cation indicators useful in the invention are set out in Haugland, R. P.
  • a divalent cation indicator refers to a molecule that is readily permeable to a cell membrane or otherwise amenable to transport into a cell e.g., via liposomes, etc., and upon entering a cell, exhibits a fluorescence signal, or other detectable signal, that is either enhanced or quenched upon contact with a divalent cation.
  • bind(s) or "bind(s) specifically” when referring to a peptide refers to a peptide molecule which has intermediate or high binding affinity, exclusively or predominately, to a target molecule.
  • the phrases “specifically binds to” refers to a binding reaction which is determinative of the presence of a target protein in the presence of a heterogeneous population of proteins and other biologies.
  • the specified binding moieties bind preferentially to a particular target protein and do not bind in a significant amount to other components present in a test sample.
  • Specific binding to a target protein under such conditions can require a binding moiety that is selected for its specificity for a particular target antigen.
  • a variety of assay formats can be used to select ligands that are specifically reactive with a particular protein. For example, solid-phase ELISA immunoassays, immunoprecipitation, Biacore and Western blot are used to identify peptides that specifically react with the antigen. Typically a specific or selective reaction is at least twice background signal or noise and more typically more than 10 times background.
  • Naturally-occurring refers to the fact that an object can be found in nature.
  • a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified in the laboratory is naturally-occurring.
  • assessing includes any form of measurement, and includes determining if an element is present or not.
  • determining includes determining if an element is present or not.
  • determining includes determining if an element is present or not.
  • determining includes determining if an element is present or not.
  • determining includes determining if an element is present or not.
  • evaluating includes determining if an element is present or not.
  • assessing includes quantitative and/or qualitative determinations. Assessing may be relative or absolute.
  • “Assessing binding” includes, e.g., determining the amount of binding, the KD for binding affinity and/or determining whether binding has occurred (i.e., whether binding is present or absent).
  • treatment refers to obtaining a desired pharmacologic and/or physiologic effect.
  • the effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse affect attributable to the disease.
  • Treatment covers any treatment of a disease in a mammal, particularly in a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting or slowing its
  • Treatment is also meant to encompass delivery of an agent to provide for a pharmacologic effect, even in the absence of a disease or condition.
  • Subject “Subject,” “individual,” “host” and “patient” are used interchangeably herein, to refer to an animal, human or non-human, amenable to a treatment according to a method of the invention.
  • the subject is a mammalian subject.
  • Exemplary subjects include humans, domestic and non-domestic animals: e.g., non-human primates, mice, rats, cattle, sheep, goats, pigs, dogs, cats, and horses; with humans being of particular interest.
  • substituents and/or variables are permissible only if such combinations result in stable compounds.
  • Optionally substituted refers to all subsequent modifiers in a term, for example in the term “optionally substituted phenyl (Ci_6)alkyl,” optional substitution may occur on both the alkyl portion and the phenyl portion of the molecule.
  • the alkyl groups herein can have one hydrogen on the alkyl backbone substituted with aromatic and heteroaromatice ring systems that are described herein, which themselves can be further optionally substituted.
  • Another example is "optionally substituted Cs_ 7 aryl-(Ci_ 6 )alkyl can be a fluoro,chloro-benzyl group.
  • Haloalkyl refers to any of the alkyl groups disclosed herein that is substituted by one or more chlorine, bromine, fluorine or iodine with fluorine and chlorine being preferred, such as chloromethyl, iodomethyl, trif uoromethyl, 2,2,2-trifluoroethyl, and 2-chloroethyl.
  • a haloalkyl can have other substitutions in addition to the halogen.
  • Substituted alkyl, aryl, and heterocyclyl refer respectively to alkyl, aryl, and heterocyclyl, wherein one or more (for example up to about five, in another example, up to about three) hydrogen atoms are replaced by a substituent independently selected.
  • Examples include fluoromethyl, hydroxypropyl, nitromethyl, aminoethyl or and the like, optionally substituted aryl (for example, 4-hydroxyphenyl, 2,3-difluorophenyl, and the like), optionally substituted arylalkyl (for example, 1-phenyl-ethyl, para- methoxyphenylethyl and the like), optionally substituted heterocyclylalkyl (for example, l-pyridin-3-yl-ethyl, N-ethylmorphonlino and the like), optionally substituted
  • heterocyclyl for example, 5-chloro-pyridin-3-yl, l-methyl-piperidin-4-yl and the like
  • alkoxy for example methoxyethoxy, hydroxypropyloxy, methylenedioxy and the like
  • amino for example, methylamino, diethylamino, trifluoroacetylamino and the like
  • alkyl group refers to a saturated aliphatic hydrocarbon, including straight- chain, branched chain, and cyclic alkyl groups. Alkyl groups can comprise any combination of acyclic and cyclic subunits. Further, the term “alkyl” as used herein expressly includes saturated groups as well as unsaturated groups. Unsaturated groups contain one or more (e.g., one, two, or three), double bonds and/or triple bonds. The term “alkyl” includes substituted and unsubstituted alkyl groups. "Lower akyl” is defined as having 1-7 carbons. Preferably, the alkyl group has 1 to 18 carbons and is straight-chain or branched.
  • the term can include a saturated linear or branched-chain monovalent hydrocarbon radical of a specified number of carbon atoms, wherein the alkyl radical may be optionally substituted independently with one or more substituents described herein.
  • Substituents can be chosen form any of the radicals, groups or moieties described herein.
  • alkyl groups include, but are not limited to, methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), 1 -propyl (n-Pr, n-propyl, -CH 2 CH 2 CH 3 ), 2- propyl (i-Pr, i-propyl, -CH(CH 3 ) 2 ), 1 -butyl (n-Bu, n-butyl, -CH 2 CH 2 CH 2 CH 3 ), 2-methyl- 1 -propyl (i-Bu, i-butyl, -CH 2 CH(CH 3 ) 2 ), 2-butyl (s-Bu, s-butyl, -CH(CH 3 )CH 2 CH 3 ), 2- methyl-2-propyl (t-Bu, t-butyl, -C(CH 3 ) 3 ), 1-pentyl (n-pentyl, -CH 2 CH 2 CH 2 CH 3 ), 2- pent
  • alkyl residue having a specific number of carbons when named, all geometric isomers having that number of carbons are intended to be encompassed; thus, for example, either “butyl” or “C 4 alkyl” is meant to include n-butyl, sec-butyl, isobutyl, t-butyl, isobutenyl and but-2-yne radicals; and for example, "propyl” includes n-propyl, propenyl, and isopropyl.
  • Ci-C 6 alkyl encompasses alkyl groups of 1 to 6 carbons. Preferably, the carbon number is one to three in all embodiments.
  • alkoxy means a straight or branched chain alkyl radical, as defined above, unless the chain length is limited thereto, bonded to an oxygen atom, including, but not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and the like.
  • the alkoxy chain is 1 to 6 carbon atoms in length, more preferably 1-4 carbon atoms in length.
  • the substitutions on alkoxy groups are similar to those on alkyl groups.
  • Haloalkoxy groups are preferred optionally substitued alkoxy groups, for example, trifluormethoxy.
  • alkylamine by itself or as part of another group refers to an amino group which is substituted with one alkyl group as defined above.
  • dialkylamine by itself or as part of another group refers to an amino group which is substituted with two alkyl groups as defined above.
  • halo or halogen by itself or as part of another group refers to chlorine, bromine, fluorine or iodine, unless defined otherwise in specific uses in the text and/or claims.
  • carbonyl refers to a C double bonded to an O, wherein the C is further covalently bound.
  • heterocycle or "heterocyclic ring”, as used herein except where noted, represents a stable 5- to 7-membered mono-heterocyclic ring system which may be saturated or unsaturated, and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O, and S, and wherein the nitrogen and sulfur heteroatom may optionally be oxidized.
  • rings contain one nitrogen combined with one oxygen or sulfur, or two nitrogen heteroatoms.
  • heterocyclyl radicals include, but are not limited to, azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazoyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrazoyl, tetrahydroisoquinolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2- oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepin
  • aryl refers to aromatic six- to fourteen-membered carbocyclic ring, for example, benzene, naphthalene, indane, tetralin, fluorene and the like.
  • the "aryl” “aromatic” and “heteroaromatic” group may be substituted with substituents including lower alkyl, hydroxyl, halo, haloalkyl, nitro, cyano, alkoxy and lower alkylamino, and the like.
  • heteroatom is used herein to mean an oxygen atom ("0"), a sulfur atom ("S”) or a nitrogen atom (“N"). When the heteroatom is nitrogen, it may form an NR moiety, wherein each R is independently from one another hydrogen or a substitution.
  • alkenyl refers to an unsaturated hydrocarbon group containing at least one carbon-carbon double bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkenyl group has 1 to 18 carbons.
  • the alkenyl group may be substituted or unsubstituted.
  • the term includes a linear or branched monovalent hydrocarbon radical of two to twelve carbon atoms with at least one site of unsaturation, i.e., a carbon-carbon, sp triple bond, wherein the alkynyl radical may be optionally substituted independently with one or more substituents described herein. Examples include ethynyl (-C ⁇ CH), propynyl (propargyl, -CH 2 C ⁇ CH), and the like.
  • cyclic refers to a saturated or partially unsaturated ring having from 5 to 12 carbon atoms as a monocyclic ring or 7 to 12 carbon atoms as a bicyclic ring.
  • Bicyclic rings having 7 to 12 atoms can be arranged, for example, as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, and bicyclic carbocycles having 9 or 10 ring atoms can be arranged as a bicyclo [5,6] or [6,6] system, or as bridged systems such as bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane and
  • monocyclic carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-l-enyl, l-cyclopent-2-enyl, 1- cyclopent-3-enyl, cyclohexyl, 1-cyclohex-l-enyl, l-cyclohex-2-enyl, l-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, and the like.
  • bicyclic radicals comprising an aromatic ring fused to a saturated, partially unsaturated ring, or aromatic carbocyclic or heterocyclic ring.
  • Typical aryl groups include, but are not limited to, radicals derived from benzene (phenyl), substituted benzenes, biphenyl, benzoamidazoles, indole, coumarin, pyranopyrole, benzothiophene, indazole, indenyl, indanyl, 1 ,2- dihydronapthalene, 1,2,3,4-tetrahydronapthyl, and the like.
  • Aryl groups are optionally substituted independently with one or more substituents described herein.
  • An "Acyl” refers to groups of from one to ten carbon atoms of a straight, branched, cyclic configuration, saturated, unsaturated and aromatic and combinations thereof, attached to the parent structure through a carbonyl functionality.
  • One or more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include acetyl, benzoyl, propionyl, isobutyryl, t-butoxycarbonyl, benzyloxycarbonyl and the like.
  • alkynyl refers to an unsaturated hydrocarbon group containing at least one carbon-carbon triple bond, including straight-chain, branched chain, and cyclic groups. Preferably, the alkynyl group has 1 to 18 carbons. The alkynyl group may be substituted or unsubstituted.
  • the term "acute insult to the central nervous system” includes short-term events that pose a substantial threat of neuronal damage mediated by glutamate excitotoxicity, or caused by trauma, inflammation TRPM7 channels, TRPM2 or other channels. as well as, longer-term propagation of stroke-induced ischemic damage mediated e.g.
  • Ischemic events may also involve inadequate blood flow, such as a stroke or cardiac arrest, hypoxic events (involving inadequate oxygen supply, such as drowning, suffocation, or carbon monoxide poisoning), trauma to the brain or spinal cord (in the form of mechanical or similar injury), certain types of food poisoning which involve an excitotoxic poison such as domoic acid, and seizure-mediated neuronal degeneration, which includes certain types of severe epileptic seizures. It can also include trauma that occurs to another part of the body, if that trauma leads to sufficient blood loss to jeopardize blood flow to the brain (for example, as might occur following a shooting, stabbing, or automobile accident).
  • Cardiovascular ischemia which is used interchangeably with “myocardial ischemia” or cardiac or heart ischemia is intended to mean acute and chronic damage in the circulatory system with cell death resulting, e.g., from hypoxia, e.g., heart attack, suffocation, carbon monoxide poisoning, trauma, pulmonary dysfunction and the like; decreased blood flow, e.g., from occlusion, atherosclerosis, diabetic microvascular insufficiency and the like; dysregulation of nitric oxide; dysfunction of the endothelium or vascular smooth muscle; and the like.
  • hypoxia e.g., heart attack, suffocation, carbon monoxide poisoning, trauma, pulmonary dysfunction and the like
  • decreased blood flow e.g., from occlusion, atherosclerosis, diabetic microvascular insufficiency and the like
  • dysregulation of nitric oxide dysfunction of the endothelium or vascular smooth muscle; and the like.
  • TRPM7 has been identified as a Mg2+ and Ca2+-regulated and calcium- permeant ion channel required for cell viability. As an ion channel, TRPM7 conducts calcium, Mg2+ and monovalent cations to depolarize cells and increase intracellular calcium. TRPM7 currents are activated at low intracellular Mg levels or low extracellular levels of divalent cations and are blocked by a number of divalent and polyvalent cations, including magnesium, zinc, spermine, 2-aminophenoxyborate, Mn(III) tetrakis (4-benzoic acid) porphyrin chloride, and lanthanum (Harteneck, Arch Pharamcol 2005 37 ⁇ 307-314).
  • TRPM7 Both Mg 2+ and Zn 2 permeate TRPM7 channels and block the movovalent cation flow through them (Kozak et al, Biophys. 2003 84:2293-2305).
  • the TRPM7 channel produces pronounced outward currents at nonphysiological voltages ranging from +50 to +100 mV and small inward currents at negative potentials between -100 to - 40 mV when expressed heterologously in mammalian cells (Jiang et al, J. Gen. Physiol. 2005 126(2), 137-150) TRPM7 has also been shown to be modulated by Src-family kinases (Jiang et al, J. Biol. Chem.
  • PIP.sub.2 phosphatidylinositol 4,5- biphosphate
  • TRPM7 channels e.g., TPRM7 channels expressed in HEK-
  • HEK-293 cells The lethality can be prevented by increasing extracellular Mg to restore Mg. 2+ homeostasis (Aarts et al, Cell 2003 115:863-877).
  • the present invention provides, inter alia, cell based systems that can be used to identify modulators, for example, inhibitors or activators of TRPM7 production or TRPM7 activity.
  • modulators for example, inhibitors or activators of TRPM7 production or TRPM7 activity.
  • the amount or activity of a TRPM7 channel can be assessed using a variety of assays, including measuring current, measuring membrane potential, measuring ion flux, measuring ligand binding, measuring second messengers and transcription levels or physiological effects such as cell survival.
  • Modulators of the TRPM7 channels can be tested using biologically active TRPM7, either recombinant or naturally occurring.
  • Murine TRPM7 can be isolated, co- expressed or expressed in a cell, or expressed in a membrane derived from a cell.
  • Samples or assays that are treated with a potential TRPM7 channel inhibitor or activator can be compared to control samples without the test compound, to examine the extent of modulation.
  • Control samples (untreated with activators or inhibitors) are assigned a relative TRPM7 activity value of 100%.
  • Inhibition of channels comprising TRPM7 is achieved when the ion channel activity value relative to the control is, for example, about 90%, preferably about 50%, more preferably about 25%.
  • Activation of channels comprising TRPM7 is achieved when the ion channel activity value relative to the control is 110%, more preferably 150%, more preferable 200% higher.
  • Changes in ion flux can be assessed by determining changes in polarization (i.e., electrical potential) of the cell membrane expressing the TRPM7 channel.
  • a preferred means to determine changes in cellular polarization is by measuring changes in current (thereby measuring changes in polarization) with voltage-clamp and patch-clamp techniques, e.g., the "cell-attached” mode, the "inside-out” mode, and the "whole cell” mode (see, e.g., Runnels et al. Science 2001 291 : 1043-1047, Jiang et al, J. Gen. Physiol. 2005 126(2), 137-150).
  • the compounds to be tested are present in the range from about 1 pM to about 100 mM.
  • the present invention provides, inter alia, methods of identifying molecules that bind TRPM7, methods of identifying molecules that modulate TRPM7 ion channel activity, and/or methods of identifying molecules that alter expression of TRPM7 within a cell. These molecules are candidate bioactive agents that can be useful for treating conditions or diseases regulated by TRPM7 activity.
  • modulators can be used in the therapeutic or prophylactic treatment of any of the diseases and diorders described herein including ischemic injuries as described herein, as well as neurodegenerative conditions, including neurological diseases and conditions, such as stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, dementia, epilepsy, spinocerebellar ataxia, spinal and bulbar muscular dystrophy, dentatorubropallidoluysian atrophy, brain injury, spinal cord injury, and other traumatic nervous system injuries.
  • neurological diseases and conditions such as stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, dementia, epilepsy, spinocerebellar ataxia, spinal and bulbar muscular dystrophy, dentatorubropallidoluysian atrophy, brain injury, spinal cord injury, and other traumatic nervous system injuries.
  • Such modulators can also be used in the therapeutic treatment of non-neurological diseases, including ischemic disorders and conditions of other tissues, such as ischemia of the heart, liver, kidneys, muscles, retina, skin, intestines, pancreas, gall bladder, thyroid, thymus, spleen, bone, cartilage, joints, lungs, diaphragm, adrenal glands, salivary and lacrimal glands, blood vessels, and cells of endothelial, mesanchymal and neural origin.
  • these methods can be used to identify drug candidates that inhibit murine TRPM7 activity.
  • the present invention provides methods of screening for a candidate bioactive agent capable of reducing TRPM7-mediated cellular injury.
  • the candidate bioactive agent binds to a particular domain of the TRPM7 protein, such as, the C-terminal kinase domain.
  • the candidate bioactive agent acts on a downstream signalling pathway that is associated and/or activated by TRPM7 activity, and that mediate the injurious consequences of TRPM7 activity on the cell.
  • either TRPM7 or a candidate bioactive agent is labeled.
  • the label can be any detectable label, such as those described herein.
  • the label provides a means of detecting the binding of the candidate agent to TRPM7.
  • TRPM7 is immobilized or covalently attached to a surface and contacted with a labeled candidate bioactive agent.
  • a library of candidate bioactive agents are immobilized to a surface or covalently attached to a surface, e.g., biochip and contacted with a labeled TRPM7.
  • the present invention provides methods for blocking or reducing murine
  • TRPM7 gene expression as well as methods for screening for a candidate bioactive agent capable of blocking or reducing TRPM7 gene expression and thus, TRPM7 activity.
  • RNA interference RNA interference
  • traditional methods of gene suppression employing anti-sense RNA or DNA, operate by binding to the reverse sequence of a gene of interest such that binding interferes with subsequent cellular processes and therefore blocks synthesis of the corresponding protein.
  • RNAi also operates on a post-translational level and is sequence specific, but suppresses gene expression far more efficiently.
  • post-transcriptional gene silencing is brought about by a sequence-specific RNA degradation process which results in the rapid degradation of transcripts of sequence-related genes.
  • Small nucleic acid molecules such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (mRNA), and short hairpin RNA (shRNA) molecules can all be used to modulate the expression of TRPM7 genes.
  • Small nucleic acid molecules capable of suppressing TRPM7 through RNA intereference can be prepared by methods known in the art. See, for example, US Publication No.
  • the present invention provides molecules capable of modulating e.g., blocking or reducing murine TRPM7 activity, as well as methods of screening for a candidate bioactive agent capable of modulating murine TRPM7 activity, such as anti- sense RNAs and DNAs, ribozymes, and other small nucleic acid molecules such as those described herein. All of these agents can be used as therapeutic agents for blocking the expression of certain TRPM7 genes in vivo. In some embodiments, they can be used to prevent TRPM7 gene transcription into mRNAs, to inhibit translation of TRPM7 mRNAs into proteins, and to block activities of preexisting TRPM7 proteins.
  • a candidate bioactive agent capable of modulating murine TRPM7 activity such as anti- sense RNAs and DNAs, ribozymes, and other small nucleic acid molecules such as those described herein. All of these agents can be used as therapeutic agents for blocking the expression of certain TRPM7 genes in vivo. In some embodiments, they can be used to prevent TRPM7 gene transcription into mRNAs
  • TRPM7 expression can be determined by RT-PCR. Methods of performing RT-PCR are known in the art and are thus, not described herein. The effect of these molecules on TRPM7 channel activity can be assessed using a variety of assays described herein, including measuring current, measuring membrane potential, measuring ion flux, and measuring cell survival.
  • the present invention provides methods for identifying molecules that modulate the divalent or monovalent cationic permeability of the TRPM7 channel.
  • Modulation of the monovalent cationic permeability of the TRPM7 channel can, for example, be determined by measuring the inward and outward currents in whole cell patch clamp assays or single-channel membrane patch assays in the presence and absence of the candidate bioactive agent.
  • the modulation of monovalent cation activity can be monitored as a function of cation currents and/or membrane-potential of a cell comprising a TRPM7 channel.
  • the modulation of membrane potential can be detected with the use of a membrane potential-sensitive probe, such as bis-(l,3-dibutylbarbituric acid)trimethine oxonol (DiBAC4(3)) (Handbook of Fluorescent Probes and Research Chemicals, 9th ed. Molecular Probes).
  • a membrane potential- sensitive probe such as bis-(l,3-dibutylbarbituric acid)trimethine oxonol (DiBAC4(3)) (Handbook of Fluorescent Probes and Research Chemicals, 9th ed. Molecular Probes).
  • a fluorescent membrane potential-sensitive probe allows rapid detection of change in membrane potential by monitoring change in fluorescence with the use of such methods as fluorescence microscopy, flow cytometry and fluorescence spectroscopy, including use of high through-put screening methods utilizing fluorescence detection (Alvarez-Barrientos, et al., "Applications of Flow Cytometry to Clinical Microbiology", Clinical Microbiology Reviews, 13(2): 167-195, (2000)).
  • Modulation of the monovalent cationic permeability of the TRPM7 channel by a candidate agent can be determined by contacting a cell that expresses TRPM7 with a monovalent cation and a monovalent cation indicator that reacts with the monovalent cation to generate a signal.
  • the intracellular levels of the monovalent cation can be measured by detecting the indicator signal in the presence and absence of a candidate bioactive agent. Additionally, the intracellular monovalent cation levels in cells that express TRPM7 with cells that do not express TRPM7 can be compared in the presence and absence of a candidate bioactive agent.
  • the monovalent cation indicator can be, for example, a sodium or potassium indicator.
  • sodium indicators include SBFI, CoroNa Green, CoroNa Red, and Sodium Green (Handbook of Fluorescent Probes and Research Chemicals, 9th ed. Molecular Probes).
  • potassium indicators include PBFI (Handbook of Fluorescent Probes and Research Chemicals, 9th ed. Molecular Probes).
  • the present invention provides methods for identifying molecules that modulate the divalent cationic permeability of the TRPM7 channel.
  • the TRPM7 channel is permeable to the divalent cations, zinc, nickel, barium, cobalt, magnesium, manganese, strontium, cadmium, and calcium (Harteneck, Arch Pharmacol 2005 371 :307-314).
  • Modulation of the divalent cationic permeability of the TRPM7 channel can, for example, be determined by measuring the inward and outward currents in whole cell patch clamp assays or single-channel membrane patch assays in the presence and absence of the candidate bioactive agent.
  • the modulation of divalent cation activity can be monitored as a function of cation currents and/or membrane-potential of a cell comprising a TRPM7 channel.
  • Modulation of the divalent cationic permeability of the TRPM7 channel by a candidate agent can be determined by contacting a cell that expresses TRPM7 with a divalent cation and a divalent cation indicator that reacts with the divalent cation to generate a signal.
  • the intracellular levels of the divalent cation can be measured by detecting the indicator signal in the presence and absence of a candidate bioactive agent. Additionally, the intracellular divalent cation levels in cells that express TRPM7 with cells that do not express TRPM7 can be compared in the presence and absence of a candidate bioactive agent.
  • the divalent cation indicator can be, for example, a fluorescent magnesium indicator. Examples of magnesium indicators include furaptra or Magfura (commercially available from Molecular ProbesTM, Invitrogen Detection Technologies).
  • the methods of the present invention include methods of detecting Ca2+ flux through TRPM7 channels.
  • the levels of intracellular Ca2+ levels are detectable, for example, using indicators specific for Ca2+.
  • Indicators that are specific for Ca2+ include, but are not limited to, fura-2, indo-1, rhod-2, fura-4F, fura-5F, fura-6F and fura-FF, fluo- 3, fluo-4, Oregon Green 488 BAPTA, Calcium Green, X-rhod-1 and fura-red (Handbook of Fluorescent Probes and Research Chemicals, 9th ed. Molecular Probes).
  • Ca2+ loading can be determined by measuring Ca2+ accumulation in the cells. See, for example, Sattler et al, J. Neurochem, 1998 71, 2349-2364 and Aarts et al, Cell 2003 115:863-877.
  • Both the levels of monovalent and divalent cations into the cell can be measured either separately or simultaneously.
  • a Ca2+ specific indicator can be used to detect levels of Ca2+ and a monovalent cation specific indicator can be used to detect levels of monovalent cation.
  • the Ca2+ indicator and the monovalent cation specific indicator are chosen such that the signals from the indicators are capable of being detected simultaneously.
  • both indicators have a fluorescent signal but the excitation and/or emission spectra of both indicators are distinct such that the signal from each indicator can be detected at the same time.
  • a Ca2+ specific indicator can be used to detect levels of Ca2+ and a membrane potential sensitive probe can be used to detect changes in the membrane potential.
  • the Ca2+ indicator and the membrane potential sensitive probe can be chosen such that the signals from the indictors and probes are capable of being detected simultaneously. For example, in some
  • both the indicator and probe have a fluorescent signal but the excitation and/or emission spectra of both indicators are distinct such that the signal from each indicator can be detected at the same time.
  • TRPM7 Before modulation of the TRPM7 channel is measured, TRPM7 is preferably activated. RPM7 channels are activated by millimolar levels of MgATP levels (Nadler et al, Nature 2001 411 :590-595). TRPM7 can be activated by altering extracellular divalent cation concentrations prior to measuring the modulation of TRPM7 activity by a candidate modulating agent. Preferably, extracellular Ca2+ concentration, extracellular Mg2+ concentration, or both are altered.
  • such alteration comprise the lowering of extracellular Mg2+ concentration by at least at least 10%, at least 20%, at least 30% at least 40% at least 50%, at least 60%, at least 70%, at least 80%, at least 90%), at least 95%, preferably at least 99%. Also preferably, such alteration comprise the lowering of extracellular Ca2+ concentration by at least at least 10%, at least 20%, at least 30% at least 40% at least 50%, at least 60%, at least 70%, at least 80%, at least 90%), at least 95%, preferably at least 99%. Also preferably, such alteration comprise the simultaneous lowering of the extracellular Ca2+ and Mg2+ concentration to the extents described herein.
  • the TRPM7 activity can be measured in intact cells, e.g., HEK-293 cells, that are transformed with a vector comprising nucleic acid encoding TRPM7 and an inducible promoter operably linked thereto. After inducement of the promoter, the
  • TRPM7 polypeptides are produced and form a TRPM7 channel. Endogenous levels of TRPM7 activity can be measured prior to inducement and then compared to the levels of TRM7 activity measured subsequent to inducement. In one embodiment, fluorescent molecules can be used to detect intracellular monovalent and divalent cation levels.
  • the candidate bioactive agents can, for example, open TRPM7 channels in a variety of cells such as cells of the nervous systems of vertebrates.
  • the candidate bioactive agents close, e.g., inhibit, TRPM7 channels in a variety of cells such as cells of the nervous system.
  • Preferred candidate bioactive agents close or inhibit TRPM7 channels.
  • the closing or inhibition of the TRPM7 channels can, for example, prevent or significantly decrease neuronal cell death following ischemic injury.
  • the candidate bioactive agents can, for example, increase the expression of TRPM7 channels in a variety of cells such as cells of the nervous systems of vertebrates.
  • the candidate bioactive agents reduce, e.g., inhibit, the expression of TRPM7 channels in a variety of cells such as cells of the nervous system.
  • Preferred candidate bioactive agents inhibit the expression of TRPM7 channels.
  • the inhibition of expression of TRPM7 channels can, for example, prevent or significantly decrease neuronal cell death following ischemic injury.
  • the candidate bioactive agents can, for example, potentiate the activity of downstream signalling pathways that depend on TRPM7 channel activity in a variety of cells such as cells of the nervous systems of vertebrates.
  • the candidate bioactive agents inhibit the activity of downstream signalling pathways that depend on TRPM7 channel activity in a variety of cells such as cells of the nervous system.
  • Preferred candidate bioactive agents inhibit the activity of downstream signalling pathways that depend on TRPM7 channel activity.
  • the inhibition of downstream signalling pathways that depend on TRPM7 channel activity can, for example, prevent or significantly decrease neuronal cell death following ischemic injury.
  • the present provides methods for identifying candidate bioactive agents that modulate expression levels of TRPM7 within cells.
  • Candidate agents can be used that wholly or partially suppress or enhance the expression of TRPM7 within cells, thereby altering the cellular phenotype.
  • Examples of these candidate agents include naturally orccuring or synthetic small molecules, antisense cDNAs and DNAs, regulatory binding proteins and/or nucleic acids, as well as any of the other candidate bioactive agents herein described that modulate transcription or translation of nucleic acids encoding TRPM7.
  • a particularly useful assay for use in the present invention measures the effect that a compound of interest has on cells expressing TRPM7 that have been exposed to conditions that activate TRPM7 channels as described herein.
  • such cells may be exposed to conditions of low extracellular Mg2+, low extracellular Ca2+ or both (Wei et al., 2007).
  • TRPM7-mediated cellular injury Assays for measuring cell survival are known in the art and include, for example, assays for measuring lactate dehydrogenase which is released from dying cells and assays for measuring ATP in living cells. A preferred candidate bioactive agent rescue cells that have undergone TRPM7 channel activation. If desired, further tests can be performed to confirm that the compound had an effect on TRPM7 gene expression or biological activity of the protein. Standard immunoassays can be used, such as western blotting, ELISA and the like. For measurement of mRNA, amplification, e.g., using PCR, LCR, or hybridization assays, e.g., northern hybridization, RNase protection, dot blotting, are preferred.
  • the level of protein or mRNA can be detected, for example, using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.
  • directly or indirectly labeled detection agents e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.
  • the compound can be used in an animal model, in particular a murine model, for ischemic injury, including, for example, stroke.
  • Another useful assay for use in the present invention measures the effect that a compound of interest has on cells expressing TRPM7 that have been denied oxygen and glucose. By measuring cell survival or cell death after the denial of oxygen and glucose and comparing the amount of cell survival in a control cell sample versus the amount of cell survival in a cell sample treated with a test compound, it can be determined whether the test compound is a modulator of TRPM7 activity and of ischemic death.
  • Assays for measuring cell survival are known in the art and include, for example, assays for measuring lactate dehydrogenase which is released from dying cells and assays for measuring ATP in living cells. A preferred candidate bioactive agent rescue cells that have been denied oxygen and glucose. If desired, further tests can be performed to confirm that the compound had an effect on TRPM7 gene expression or biological activity of the protein as described herein.
  • TRPM7 expression is inducible.
  • the effects of a compound of interest has on the cells expressing TRPM7 is compared between the effect measured when the compound of interest is contacted with the cells prior to the induction of TRPM7 expression, preferably at a time ranging from 0 to 3 days prior to induction of TRPM7 expression, with the effects that the same compound of interest has on the cells expressing TRPM7 when the compound of interest is applied at or after the activation of TRPM7, preferably at a time ranging from 0 to 36 hours after the activation of TRPM7.
  • the TRPM7 used in these assays has at least 99% identity to the amino acid sequence as set forth in Swiss- Prot Q923J1 [mouse], Q925B3 [rat], or Q96QT4 [human].
  • the various screening methods described vary in length of time needed to perform and information generated. For screening large numbers of agents (e.g., greater than 10,000) methods can be combined with a primary highthroughput screen performed on random compounds, and a secondary screen performed on agents showing a positive result in the first screen.
  • a useful primary screen is to measure the effect of an agent on cell death/survival of cells expressing TRMP7 (either naturally or recombinantly).
  • TRMP7 is activated before performing the assay by decreasing the
  • bivalent ion e.g., Ca or Mg
  • concentration of bivalent ion in the culture media.
  • the concentration can be changed by changing the culture media or simply by dilution. In the absence of an agent, a significant portion of cells die.
  • some agents have a protective function against cell death. This protective function can be assessed from any measure of cell death or survival. Because cell death and survival are reciprocal events, a measurement of one effectively serves as a measure of the other.
  • Some agents identified by the assay inhibit cell death or in other words promote cell survival. Other agents have the opposite effect of promoting cell death or inhibiting cell survival. Other agents have no effect in such an assay. Such effects are typically demonstrated relative to a control assay in which the agent being tested is not present.
  • Agents identified by the primary screen are inhibitors or activators of TRPM7-mediated cell death.
  • the agents need not act directly to inhibit expression or functional activity of TRPM7.
  • some agents may upstream or downstream in a molecular pathway by which TRPM7 mediated cells death occurs.
  • a secondary assay can be performed on agents found to inhibit or promote TRPM7-mediated cell death in the primary assay.
  • the secondary assay measure an effect on ion currents through a TRMP7 ion channel as described in the examples.
  • An ability to inhibit or promote such ion currents demonstrates the agent has a specific effect on TRPM7 activity, which may be directly on the channel although could also be indirect via upstream activation.
  • Additional tertiary assays can be performed on agents found to inhibit or promote ion currents in a TRPM7 channel can be further tested for pharmacological activity in treatment or prophylaxis of disease in cellular or animal models of disease, including any of the diseases described herein.
  • models include cellular and animal models of ischemia, including stroke.
  • Agents having positive activity in disease models e.g., which reduce infarct size or reduce cognitive deficit
  • cancer, pain or glaucoma can be carried forward into clinical trials and then used as pharmaceuticals in indications, such asthose described herein.
  • Additional assays can be performed in combination with the primary, second and tertiary assays described above. For example, following the primary assay, it can be useful to perform a dose response analysis on agents showing positive results from the primary assay. Existence of a dose response provides a safeguard against false positives as well as allowing more accurate comparison of potency of different agents and selection of which agents to carry forward to the secondary assay.
  • TRPM7 or inhibits expression of a TRPM7 protein.
  • assays can performed before or after the primary screen described above and are useful in selecting from a larger pool, agents that act specificially on TRPM7 or its expression.
  • modulator means either molecule, e.g., protein, oligopeptide, small organic molecule,
  • the term "candidate bioactive agent” as used herein describes any molecule that binds to TRPM7, modulates the activity of a TRPM7 ion channel, alters the expression of TRPM7 within cells, or reduces the damaging effects of TRPM7 channel activation on cells by inhibiting TRPM7-depedent
  • Candidate agents may be bioactive agents that are known or suspected to bind to ion channel proteins or known to modulate the activity of ion channel proteins, or alter the expression of ion channel proteins within cells.
  • Candidate agents can also be mimics of bioactive agents that are known or suspected to bind to ion channel proteins or known to modulate the activity of ion channel proteins, or alter the expression of ion channel proteins within cells.
  • the candidate agents induce a response, or maintain such a response as indicated, for example, reduction of neuronal cell death following ischemic injury.
  • Candidate agents encompass numerous chemical classes, though typically they are organic molecules.
  • Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides.
  • libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced.
  • natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means.
  • Known pharmacological agents can be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification,
  • the invention provides methods for identifying/screening for modulators (e.g., inhibitors, activators) of murine TRPM7 activity.
  • a candidate compound is provided.
  • Combinatorial chemical libraries are one means to assist in the generation of new chemical compound leads for, e.g., compounds that inhibit a murine TRPM7 activity.
  • a combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building blocks" such as reagents.
  • a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks. For example, the systematic, combinatorial mixing of 100 interchangeable chemical building blocks results in the theoretical synthesis of 100 million tetrameric compounds or 10 billion pentameric compounds. (See, e.g., Gallop et al, J. Med. Chem. 1994, 37: 1233-1250). Preparation and screening of combinatorial chemical libraries are well known to those of skill in the art, (see, e.g., U.S. Pat. Nos. 6,004,617; 5,985,356). Such combinatorial chemical libraries include, but are not limited to, peptide libraries, (see, e.g., U.S. Pat. No.
  • chemistries for generating chemical diversity libraries include, but are not limited to: peptoids (see, e.g., WO 91/19735), encoded peptides (see, e.g., WO 93/20242), random bio-oligomers (see, e.g., WO 92/00091), benzodiazepines (see, e.g., U.S. Pat. No.
  • oligocarbamates see, e.g., Cho, Science 1993, 261 : 1303), and/or peptidyl phosphonates (see, e.g., Campbell, J. Org. Chem. 1994, 59: 658). See also (Gordon, J. Med. Chem. 1994, 37: 1385); for nucleic acid libraries, peptide nucleic acid libraries, (see, e.g., U.S. Pat. No. 5,539,083); for antibody libraries, (see, e.g., Vaughn, Nature Biotechnology 1996, 14: 309-314); for carbohydrate libraries, (see, e.g., Liang et al, Science 1996, 274: 1520-1522, U.S.
  • a number of robotic systems have also been developed for solution phase chemistries. These systems include automated workstations, e.g., like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton, Mass.; Orca, Hewlett-Packard, Palo Alto, Calif.) that mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use with the present invention.
  • the compounds tested as modulators of murine TRPM7 genes or gene products can be any small organic molecule, or a biological entity, such as a protein, e.g., an antibody or peptide, a sugar, a nucleic acid, e.g., an antisense oligonucleotide or RNAi, or a ribozyme, or a lipid.
  • modulators can be genetically altered versions of a murine TRPM7 protein.
  • test compounds are small organic molecules (molecular weight no more than 1000 and usually no more than 500 Da), peptides, lipids, and lipid analogs.
  • any chemical compound can be used as a potential modulator or ligand in the assays of the invention, although most often compounds can be dissolved in aqueous or organic (especially DMSO-based) solutions are used.
  • the assays are designed to screen large chemical libraries by automating the assay steps and providing compounds from any convenient source to assays that are typically run in parallel (e.g., in microtiter formats on microtiter plates in robotic assays). It will be appreciated that there are many suppliers of chemical compounds, including Sigma (St. Louis, Mo.), Aldrich (St. Louis, Mo.), Sigma-Aldrich (St. Louis, Mo.), Fluka Chemika-Biochemica Analytika (Buchs Switzerland) and the like.
  • high throughput screening methods involve providing a combinatorial small organic molecule or peptide library containing a large number of potential therapeutic compounds (potential modulator or ligand compounds). Such "combinatorial chemical libraries” or “ligand libraries” (as described above) are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.
  • the invention provide soluble assays using molecules such as a domain such as ligand binding domain, an active site, and the like; a domain that is covalently linked to a heterologous protein to create a chimeric molecule; murine TRPM7; a cell or tissue expressing murine TRPM7, either naturally occurring or recombinant.
  • the invention provides solid phase based in vitro assays in a high throughput format, where the domain, chimeric molecule, murine TRPM7, or cell or tissue expressing murine TRPM7 is attached to a solid phase substrate.
  • exemplary high throughput assays of the invention it is possible to screen up to several thousand different modulators or ligands in a single day.
  • each well of a microtiter plate can be used to run a separate assay against a selected potential modulator, or, if concentration or incubation time effects are to be observed, every 5-10 wells can test a single modulator.
  • a single standard microtiter plate can assay about 100 (e.g., 96) modulators. If 1536 well plates are used, then a single plate can easily assay from about 100-1500 different compounds. It is possible to assay several different plates per day; assay screens for up to about 6,000-20,000 different compounds is possible using the integrated systems of the invention.
  • the molecule of interest can be bound to the solid state component, directly or indirectly, via covalent or non covalent linkage, e.g., via a tag.
  • the tag can be any of a variety of components.
  • a molecule that binds the tag (a tag binder) is fixed to a solid support, and the tagged molecule of interest is attached to the solid support by interaction of the tag and the tag binder.
  • tags and tag binders can be used, based upon known molecular interactions well described in the literature.
  • a tag has a natural binder, for example, biotin, protein A, or protein G, it can be used in conjunction with appropriate tag binders (avidin, streptavidin, neutravidin, the Fc region of an
  • Antibodies to molecules with natural binders such as biotin are also widely available and appropriate tag binders; see, SIGMA
  • any haptenic or antigenic compound can be used in combination with an appropriate antibody to form a tag/tag binder pair.
  • Thousands of specific antibodies are commercially available and many additional antibodies are described in the literature.
  • the tag is a first antibody and the tag binder is a second antibody that recognizes the first antibody.
  • receptor- ligand interactions are also appropriate as tag and tag-binder pairs.
  • agonists and antagonists of cell membrane receptors e.g., cell receptor- ligand interactions such as transferrin, c-kit, viral receptor ligands, cytokine receptors, chemokine receptors, interleukin receptors, immunoglobulin receptors and antibodies, the cadherein family, the integrin family, the selectin family, and the like; see, e.g., Pigott et al., The Adhesion Molecule Facts Book 1 , 1993.
  • toxins and venoms, viral epitopes, hormones (e.g., opiates, steroids, and the like), intracellular receptors e.g.
  • Synthetic polymers such as polyurethanes, polyesters, polycarbonates, polyureas, polyamides, polyethyleneimines, polyarylene sulfides, polysiloxanes, polyimides, and polyacetates can also form an appropriate tag or tag binder. Many other tag/tag binder pairs are also useful in assay systems described herein, as would be apparent to one of skill upon review of this disclosure.
  • Common linkers such as peptides, polyethers, and the like can also serve as tags, and include polypeptide sequences, such as poly gly sequences of between about 5 and 200 amino acids.
  • polypeptide sequences such as poly gly sequences of between about 5 and 200 amino acids.
  • Such flexible linkers are known to persons of skill in the art.
  • poly(ethylene glycol) linkers are available from Shearwater Polymers, Inc. Huntsville, Ala. These linkers optionally have amide linkages, sulfhydryl linkages, or hetero functional linkages.
  • Tag binders can be fixed to solid substrates using any of a variety of methods currently available.
  • Solid substrates are commonly derivatized or functionalized by exposing all or a portion of the substrate to a chemical reagent that fixes a chemical group to the surface that is reactive with a portion of the tag binder.
  • groups that are suitable for attachment to a longer chain portion would include amines, hydroxyl, thiol, and carboxyl groups.
  • Aminoalkylsilanes and hydroxyalkylsilanes can be used to functionalize a variety of surfaces, such as glass surfaces. The construction of such solid phase biopolymer arrays is well described in the literature. (See, e.g.,
  • Non-chemical approaches for fixing tag binders to substrates include other common methods, such as heat, cross-linking by UV radiation, and the like.
  • Compounds that modulate murine TRPM7 activity can also be determined by computer assisted drug design, in which a computer system is used to generate a three- dimensional structure of murine TRPM7 based on the structural information encoded by the amino acid sequence.
  • the input amino acid sequence interacts directly and actively with a preestablished algorithm in a computer program to yield secondary, tertiary, and quaternary structural models of the protein.
  • the models of the protein structure are then examined to identify regions of the structure that have the ability to bind, e.g., ligands. These regions are then used to identify ligands that bind to the protein.
  • the three-dimensional structural model of the protein is generated by entering murine TRPM7 amino acid sequences of at least 10 amino acid residues or
  • nucleic acid sequences encoding a murine TRPM7 polypeptide into the computer system.
  • the amino acid sequence of the polypeptide or the nucleic acid encoding the polypeptide is selected from the group consisting of the sequences provided herein, and conservatively modified versions thereof.
  • the amino acid sequence represents the primary sequence or subsequence of the protein, which encodes the structural information of the protein.
  • At least 10 residues of the amino acid sequence are entered into the computer system from computer keyboards, computer readable substrates that include, but are not limited to, electronic storage media (e.g., magnetic diskettes, tapes, cartridges, and chips), optical media (e.g., CD ROM), information distributed by internet sites, and by RAM.
  • the three-dimensional structural model of the protein is then generated by the interaction of the amino acid sequence and the computer system, using software known to those of skill in the art.
  • the three-dimensional structural model of the protein can be saved to a computer readable form and be used for further analysis (e.g., identifying potential ligand binding regions of the protein and screening for mutations, alleles and interspecies homo logs of the gene).
  • the amino acid sequence represents a primary structure that encodes the information necessary to form the secondary, tertiary and quaternary structure of the protein of interest.
  • the software looks at certain parameters encoded by the primary sequence to generate the structural model. These parameters are referred to as "energy terms,” and primarily include electrostatic potentials, hydrophobic potentials, solvent accessible surfaces, and hydrogen bonding. Secondary energy terms include van der Waals potentials. Biological molecules form the structures that minimize the energy terms in a cumulative fashion. The computer program is therefore using these terms encoded by the primary structure or amino acid sequence to create the secondary structural model.
  • the tertiary structure of the protein encoded by the secondary structure is then formed on the basis of the energy terms of the secondary structure.
  • the user at this point can enter additional variables such as whether the protein is membrane bound or soluble, its location in the body, and its cellular location, e.g., cytoplasmic, surface, or nuclear. These variables along with the energy terms of the secondary structure are used to form the model of the tertiary structure.
  • the computer program matches hydrophobic faces of secondary structure with like, and hydrophilic faces of secondary structure with like.
  • potential ligand binding regions are identified by the computer system.
  • Three-dimensional structures for potential ligands are generated by entering amino acid or nucleotide sequences or chemical formulas of compounds, as described above.
  • the three-dimensional structure of the potential ligand is then compared to that of the murine TRPM7 protein to identify ligands that bind to murine TRPM7. Binding affinity between the protein and ligands is determined using energy terms to determine which ligands have an enhanced probability of binding to the protein.
  • the software can then also be used to modify the structure of a candidate ligand in order to modify (e.g., enhance or diminish) its affinity to the protein.
  • each candidate ligand may be used as a "lead compound" for the generation of other candidate ligands by the computer system.
  • the results such as three-dimensional structures for potential ligands and binding affinity of ligands, can also be saved to a computer readable form and can be used for further analysis (e.g., generating a three dimensional model of mutated proteins having an altered binding affinity for a ligand, or generating a list of additional candidate ligands for chemical synthesis).
  • the invention provides several genera and examples of compounds.
  • the compounds can be provided as they are as a pharmaceutically acceptable salt or as pharmaceutical composition.
  • Functional properties of compounds include any or all of specific binding to TRPM7, inhibiting TRMP7-mediated cell death, inhibiting TRPM7 currents, inhibiting damaging effects of ischemia (e.g., cell death) in any of the tissues disclosed herein, as demonstrated in any of the assays of the Examples (among others), inhibiting proliferation, toxicity or metastasis of cancers of any of the types disclosed herein, as demonstrated by any of the assays in the Examples (among others), inhibiting pain, and/or inhibiting damaging effects of glaucoma (e.g., cell death).
  • ischemia e.g., cell death
  • Preferred compounds exhibit any or all of the properties of TRPM7 inhibitors or candidate bioactive molecules described herein.
  • a preferred compound inhibits TRMPM7-mediated cell death in a mammalian cell by at least 30, 40, 50, 60, 70 or 80% as illustrated by the compounds in Table 3.
  • the TRPM7 used in such assays can be human (Swiss prot Q96QT4), mouse or other mammalian origin.
  • cellular or animal systems used to demonstrate functional properties can be human, mouse or other mammalian. Because the primary therapeutic use of the compounds is usually in treating humans, it is preferred that binding and other functional effects occur on materials of human orign.
  • Z, Z', J, J', E, E', L, M and M' are each independently S, O, N or C, wherein N or C in each instance can be further covalently bound to X, X', Y or Y',
  • X and X' are each independently selected from the group consisting of hydrogen, hydroxyl, optionally substituted, saturated or unsaturated Ci-C 6 alkyl, Ci-C 6 alkenyl, Ci-C 6 alkynyl, Ci-C 6 alkoxy, Ci-C 6 alkoxycarbonyl, amino, Ci-C 6 alkylamino, di-(Ci- C 6 ) alkylamino, halogen, thiol, cyano, nitro, and optionally substituted 5- to 7- member cyclic, heterocyclic, bicyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic, or is O, which taken together with a C to which it is attached forms a carbonyl,
  • Y and Y' are each independently selected from the group consisting of hydrogen, hydroxyl, optionally substituted, saturated or unsaturated Ci-C 6 alkyl, Ci-C 6 alkenyl, Ci-C 6 alkynyl, Ci-C 6 alkoxy, Ci-C 6 alkoxycarbonyl, amino, Ci-C 6 alkylamino, di-(Ci- C 6 ) alkylamino, halogen, thiol, cyano, nitro, and optionally substituted 5- to 7- member cyclic, heterocyclic, bicyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic, or is O, which taken together with a C to which it is attached forms a carbonyl,
  • A is NR a , S0 2 , , wherein x is an integer from zero to four,
  • D is carbonyl, sulfoxide, O, S or (CR 3 R 4 ) y , wherein y is an integer from zero to four,
  • U is C-(R 7 ) q or N, wherein C-R 7 can be taken together to form a carbonyl when p is zero, or R 7 is as described below,
  • p is one or zero
  • t is one or zero
  • u is one or zero
  • R is selected from the group consisting of hydrogen, optionally substituted Ci-C 6 alkyl, optionally substituted phenyl (Ci-C 6 ) alkyl, and optionally substituted 5- to 10- member cyclic, heterocyclic, bicyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic,
  • R' is selected from the group consisting of optionally substituted Ci-C 6 alkyl, optionally substituted phenyl (Ci-C 6 ) alkyl, and optionally substituted 5- to 10- member cyclic, heterocyclic, bicyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic,
  • R and R' are taken together with U to form an optionally substituted 5- to 10- member cyclic, bicyclic, heterocyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic, and
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R a and R b are each independently selected from the group consisting of hydrogen, optionally substituted Ci-C 6 alkyl, Ci-C 6 alkenyl, Ci-C 6 alkynyl, optionally substituted phenyl (Ci-C 6 ) alkyl, optionally substituted 5- to 10- member cyclic, heterocyclic, bicyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic.
  • Examples of such compounds include M4, M5, M6, M9, Ml 7, M21, M29 (Figs. 11-16) and C04, C06, CIO, C07, C08, C13, C15, D03, Dl l, D19, E07, E09, G17, G18, H06, H16, H21, 104, 114, 108, 110, 120, J08, K06, K16, C07, Cl l, C20, D09, D19, E18, F18, Gi l, G16, H19, and H20 (Table 3).
  • Z is S, O, N-H or C-H
  • X is halogen
  • Y and Y' are each independently selected from the group consisting of hydrogen, hydroxyl, optionally substituted saturated or unsaturated Ci-C 6 alkyl, Ci-C 6 alkenyl, Ci- C 6 alkynyl, Ci-C 6 alkoxy, amino, Ci-C 6 alkylamino, di-(Ci-C 6 ) alkylamino, halogen, thiol, cyano, nitro, and optionally substituted 5- to 7- member cyclic, heterocyclic, bicyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic, or is O, which taken together with a C to which it is attached forms a carbonyl,
  • A is NR a or (CR 1 R 2 ) X , wherein x is an integer from zero to four,
  • D is carbonyl or (CR 3 R 4 ) y , wherein y is an integer from zero to four,
  • G is NR b or (CR 5 R 6 ) Z , wherein z is an integer from zero to four,
  • U is C-(R 7 )q or N, wherein C-R 7 taken together are carbonyl and p is zero, or R 7 is as described below,
  • p is one or zero
  • R is hydrogen, optionally substituted Ci-C 6 alkyl, Ci-C 6 alkenyl, Ci-C 6 alkynyl, optionally substituted phenyl (Ci-C 6 ) alkyl, or an optionally substituted 5- to 10- member cyclic, heterocyclic, bicyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic,
  • R' is selected from the group consisting of optionally substituted Ci-C 6 alkyl, optionally substituted phenyl (Ci-C 6 ) alkyl, Ci-C 6 alkenyl, Ci-C 6 alkynyl, optionally substituted 5- to 10- member cyclic, heterocyclic, bicyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic,
  • R and R' are taken together with U to form an optionally substituted 5- to 10- member cyclic, bicyclic, heterocyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic, and
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R a and R b are each independently selected from the group consisting of substituted Ci-C 6 alkyl, Ci-C 6 alkenyl, Ci-C 6 alkynyl, optionally substituted phenyl (Ci-C 6 ) alkyl, optionally substituted 5- to 10- member cyclic, heterocyclic, bicyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic.
  • Some such compounds have a structure wherein R, R' and U are taken together to form a ring selected from the group consisting of
  • V, V 1 , V 2 , V 3 and V 4 in each instance are independently selected from the group consisting of N, C and O, wherein N or C can be further covalently bound to Q", Q ⁇ Q 2 , Q 3 , Q 4 or Q 5 ,
  • g is zero, one or two and
  • Q, Q', Q", Q 1 , Q 2 , Q 3 , Q 4 and Q 5 are each independently selected from the group consisting of hydrogen, hydroxyl, optionally substituted Ci-C 6 alkyl, Ci-C 6 alkenyl, Ci- C 6 alkynyl, optionally substituted phenyl (Ci-C 6 ) alkyl, Ci-C 6 alkoxy, amino, Ci-C 6 alkylamino, di-(Ci-Ce) alkylamino, halogen, thiol, cyano, nitro, and optionally substituted 5- to 7- member cyclic, heterocyclic, bicyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic, optionally substituted C5-C 7 aryl- or heteroaryl-thiamide, optionally substituted C5-C 7 aryl- or heteroaryl-carboxy, optionally substituted C5-C7 aryl- or heteroaryl-(Ci-C6) al
  • the ring has the following structure
  • Z in Formula II is S, and/or X is chlorine and/or Y and Y' are each hydrogen and/or D is carbonyl, x is zero and y is zero.
  • Q and Q' are each independently selected from the group consisting of hydrogen, hydroxyl, optionally substituted Ci-C 6 alkyl, optionally substituted phenyl (Ci-C 6 ) alkyl, Ci-C 6 alkoxy, amino, Ci-C 6 alkylamino, di-(Ci-Ce) alkylamino and halogen.
  • Q can be hydrogen, methoxy, ethoxy, propoxy, methyl, ethyl or propyl and Q' can be methoxy, ethoxy, propoxy, methyl, ethyl or propyl.
  • M6 and some related compounds can be represented by the compound of Formula III
  • Z is S
  • X is chlorine
  • Y and Y' are each hydrogen
  • U is C-(R 7 ) q .
  • R and R' are taken together with U to form an optionally substituted 5- to 10-member cyclic, bicyclic, heterocyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic.
  • M6 has the structure
  • D is carbonyl
  • X is zero
  • Z is zero
  • U is N.
  • R is selected from the group consisting of hydrogen, optionally substituted Ci-C 6 alkyl, optionally substituted phenyl (Ci-C 6 ) alkyl, Ci-C 6 alkenyl, Ci-C 6 alkynyl, and optionally substituted 5- to 10- member cyclic, heterocyclic, bicyclic or heterobicyclic ring, wherein the ring may be aromatic or heteroaromatic
  • R' is selected from the group consisting of optionally substituted Ci-C 6 alkyl, optionally substituted phenyl (Ci-C 6 ) alkyl, Ci-C 6 alkenyl, Ci-C 6 alkynyl, and optionally substituted 5- to 10- member cyclic, heterocyclic, bicyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic.
  • R is hydrogen or Ci
  • one of E, E', M and M' is C-Y, and the others are C-H.
  • Y is selected from the group consisting of hydrogen, hydroxyl, and optionally substituted, saturated or unsaturated Ci-C 6 alkyl, Ci-C 6 alkoxy and Ci-C 6 alkoxycarbonyl, or is O, which taken together with a C to which it is attached forms a carbonyl
  • X and X' are each independently selected from the group consisting of hydrogen, hydroxyl, and optionally substituted, saturated or unsaturated Ci-C 6 alkyl, Ci- C 6 alkoxy and Ci-C 6 alkoxycarbonyl, or is O, which taken together with a C to which it is attached forms a carbonyl.
  • M21 and related compounds are a preferred example of this formula and can be represented by Formula V
  • Y is hydrogen, hydroxyl, Ci-C 6 alkoxy, Ci-C 6 alkyl, amino, Ci-C 6 alkylamino, di-(Ci-Ce) alkylamino or halogen
  • X' is hydrogen, hydroxyl, Ci-C 6 alkoxy, Ci-C 6 alkyl, amino, Ci-C 6 alkylamino, di-(Ci- C 6 ) alkylamino or halogen, or is O, which taken together with a C to which it is attached forms a carbonyl
  • X is hydrogen, hydroxyl, Ci-C 6 alkoxy, Ci-C 6 alkyl, amino, Ci-C 6 alkylamino, di-(Ci-Ce) alkylamino or halogen, or is O, which taken together with a C to which it is attached forms a carbonyl
  • J is C-H, CH 2 or O.
  • X' is hydrogen, hydroxyl, Ci-C 6 alkoxy or Ci-C 6 alkyl
  • Y is hydrogen, hydroxyl, Ci-C 6 alkoxy or Ci-C 6 alkyl
  • Q and Q' are each independently selected from the group consisting of hydrogen, hydroxyl, optionally substituted Ci-C 6 alkyl, Ci-C 6 alkenyl, Ci-C 6 alkynyl, optionally substituted phenyl (Ci-C 6 ) alkyl, Ci-C 6 alkoxy, amino, Ci-C 6 alkylamino, di-(Ci-C 6 ) alkylamino, halogen, thiol, cyano, nitro, and optionally substituted 5- to 7- member cyclic, heterocyclic, bicyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic.
  • a preferred example of such compounds is M21 having the structure
  • Y is hydrogen, hydroxyl, Ci-C 6 alkoxy or Ci-C 6 alkyl
  • Q and Q' are each independently selected from the group consisting of hydrogen, hydroxyl, optionally substituted Ci-C 6 alkyl, Ci-C 6 alkenyl, Ci-C 6 alkynyl, optionally substituted phenyl (Ci-C 6 ) alkyl, Ci-C 6 alkoxy, amino, Ci-C 6 alkylamino, di-(Ci-C 6 ) alkylamino, halogen, thiol, cyano, cyano(Ci-C 6 )alkyl, nitro, optionally substituted 5- to 7- member cyclic, heterocyclic, bicyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic, optionally substituted C 5 -C 7 aryl- or heteroaryl-thiamide, optionally substituted C5-C 7 aryl- or heteroaryl-carboxy, optionally substituted C5-C 10 aryl-S-, optionally substituted phenyl-S0 2
  • Q and Q' are each independently selected from the group consisting of hydrogen, hydroxyl, optionally substituted Ci-C 6 alkyl, Ci-C 6 alkenyl, Ci-C 6 alkynyl, optionally substituted phenyl (Ci-C 6 ) alkyl, Ci-C 6 alkoxy, amino, Ci-C 6 alkylamino, di-(Ci-C6) alkylamino, halogen, thiol, cyano, nitro, and optionally substituted 5- to 7- member cyclic, heterocyclic, bicyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic
  • E is C-R , N, S or O
  • R , R , R" and R" are each independently selected from the group consisting of hydrogen, hydroxyl, optionally substituted, saturated or unsaturated Ci-C 6 alkyl, Ci- C 6 alkenyl, Ci-C 6 alkynyl, Ci-C 6 alkoxy, Ci-C 6 alkoxycarbonyl, amino, Ci-C 6
  • alkylamino di-(Ci-C 6 ) alkylamino, halogen, thiol, cyano, nitro, and optionally substituted 5- to 7- member cyclic, heterocyclic, bicyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic,
  • A is NR C , S0 2 or carbonyl
  • G is NR C , S0 2 or carbonyl
  • R z " and R" are each independently selected from the group consisting of hydrogen, hydroxyl, optionally substituted, saturated or unsaturated Ci-C 6 alkyl, Ci-C 6 alkenyl, Ci-C 6 alkynyl, Ci-C 6 alkoxy, Ci-C 6 alkoxycarbonyl, amino, Ci-C 6 alkylamino, di-(Ci-Ce) alkylamino, halogen, thiol, cyano, nitro
  • n is an integer from zero to 5
  • p is an integer from zero to 5
  • R 26 is selected from the group consisting of hydrogen, hydroxyl, optionally substituted, saturated or unsaturated Ci-C 6 alkyl, Ci-C 6 alkenyl, Ci-C 6 alkynyl, Ci-C 6 alkoxy, Ci-C 6 alkoxycarbonyl, amino, Ci-C 6 alkylamino, di-(Ci- C 6 ) alkylamino, halogen, thiol, cyano, nitro, and optionally substituted 5- to 7- member cyclic, heterocyclic, bicyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic,
  • R is hydrogen, hydroxyl or Ci-C 6 alkyl
  • U is an optionally substituted 5- to 7- member cyclic, heterocyclic, bicyclic or heterobicyclic ring, wherein said ring may be aromatic or heteroaromatic, provided that one of A and G is carbonyl or S0 2 and the other is NR C .
  • U is CR D R 'R S .
  • R is an optionally substituted 5- to 7- member cyclic, heterocyclic, bicyclic or heterobicyclic
  • R is an optionally substituted 5- to 7- member cyclic, heterocyclic, bicyclic or heterobicyclic
  • R 26 is an optionally substituted 6 member cyclic ring, wherein said ring
  • R is an optionally substituted 6 member cyclic ring, wherein said ring may be aromatic or heteroaromatic.
  • R , R , R and R are each independently selected from the group consisting of hydrogen, hydroxyl, optionally substituted, saturated or unsaturated Ci-C 6 alkyl, Ci-C 6 alkenyl, Ci-C 6 alkynyl, Ci-C 6 alkoxy, Ci-C 6 alkoxycarbonyl, amino, Ci-C 6 alkylamino, di-(Ci-C 6 ) alkylamino, halogen, thiol, cyano and nitro.
  • R , R , R , R and R are each independently selected from the group consisting of hydrogen and halogen, n is zero, p is zero, and E is C-R 20 , wherein R 20 is hydrogen.
  • A, B, D, E and G are each independently S, O, N or C, wherein N or C in each instance can be further covalently bound to L, L', R 40 or R 41 , provided that at least two of A, B, D, E and G are other then C;
  • L is -CR 44 R 45 -, -CR 44 R 45 -S0 2 -, -CR 44 R 45 -S-, Ci-C 6 alkenyl, carbonyl, S0 2 or - CR 44 -, when is a double bond,
  • q is one or zero
  • R is an optionally substituted 5- to 7- member aromatic or hetero aromatic ring
  • R 40 and R 41 are each independently selected from the group consisting of hydrogen, hydroxyl, optionally substituted, saturated or unsaturated Ci-C 6 alkyl, (Ci- C 6 )alkyl-S-(Ci-C 6 )alkyl, Ci-C 6 alkenyl, Ci-C 6 alkynyl, Ci-C 6 alkoxy, Ci-C 6
  • alkoxycarbonyl amino, Ci-C 6 alkylamino, di-(Ci-C 6 ) alkylamino, halogen, thiol, cyanomethyl, cyano and nitro, or is O, which taken together with a C to which it is attached forms a carbonyl,
  • L' is carbonyl, (CO)O, S0 2 , -( CR 46 R 47 ) m -, piperidinyl, piperazinyl,
  • n is an integer from one to four
  • n is an integer from one to four
  • s is one or zero
  • t is one or zero
  • R 43 is hydrogen or an optionally substituted 5- to 7- member aromatic or heteroaromatic ring.
  • q is zero and R is mono-, di- or tri-substituted 5 or 6 member aromatic or heteroaromatic ring.
  • R is mono-, di- or tri-substituted 5 or 6 member aromatic or heteroaromatic ring.
  • R is a mono-, di- or tri-substituted phenyl. Some such compounds have a structure of any of Formulae XII, XIII, XIV, XV, XVI, XVII, XVIII and XIX
  • R is a mono-, di- or tri-substituted phenyl
  • R 40 and R 41 are each independently selected from the group consisting of hydrogen, hydroxyl, optionally substituted, saturated or unsaturated Ci-C 6 alkyl, (Cj- C 6 )alkyl-S-(Ci-C 6 )alkyl, Ci-C 6 alkenyl, Ci-C 6 alkynyl, Ci-C 6 alkoxy, Ci-C 6
  • alkoxycarbonyl amino, Ci-C 6 alkylamino, di-(Ci-Ce) alkylamino, halogen, thiol, cyanomethyl and cyano,
  • n is an integer from one to three
  • R 43 is an optionally substituted 5- to 7- member aromatic or hetero aromatic ring.
  • R 40 and R 41 are each independently selected from the group consisting of hydrogen and Ci-C 6 alkyl, and
  • R 43 is a mono-, di- or tri-substituted phenyl.
  • Ml 4 and Ml 5 are examples of such structures as shown below.
  • Figs. 11-16 Thirty preferred agents that inhibit TRPM7-mediated cell death are shown in Figs. 11-16. All of these agents inhibited TRPM7-mediated cell death in the primary screen described above. Most of these agents showed a distinct dose-response effect. Some of these agents including at least agents #'s 5, 6, 7, 11, 14 and 21 inhibited ion currents through TRPM7 (not all agents were tested). The agents were also tested in various cellular and animal disease models as indicated in the table. In each case, where the Figures show an assay was performed, the result was positive (i.e., the agent inhibited at above background levels). If the Figures do not show a particular assay for a compound, the assay was not performed.
  • M5 is effective in inhibiting proliferation of various cancer cell lines providing evidence of utility of M5 and related comopunds in treatment or prophylaxis of cancer, particularly, retinoblastoma, breast cancer, melanoma, adrenal carcinoma and cervical cancer. M5 is also effective in increasing survival after anoxia in neurons, heptocytes, cardiomyoctes, and retina providing evidence of utitlity of M5 and related compounds in treatment and prophylaxis of ischemia, particularly of the CNS, brain, liver, heart and retina.
  • M6 is also effective in inhibiting proliferation of various cancer cell lines providing evidence of utility of M6 and related compounds in treatment or prophylaxis of cancer, particularly of retinoblastoma, breast cancer, melanoma, adrenal carcinoma, cervical cancer, osteosacrcoma, lung cancer, non-small cell lung cancer, colon cancer, and renal cancer. M6 is also effective in increasing survival after anoxia in neurons and cardiomyocytes providing evidence of utility of M6 and related compounds in treatment or prophylaxis of ischemia, particularly for the heart, CNS and brain.
  • M7 and Ml 4 are effective in inhibiting proliferation of a retinoblastoma cell line providing evidence of utility of M7, M14 and related compounds in treatment of cancer, particularly retinoblastoma.
  • M7 and M14 are also effective in increasing survival after anoxia in neurons providing evidence of utility of M7, M14 and related compounds in treatment and prophylaxis of ischemia, particularly of the brain and CNS.
  • Ml 1 is effective in inhibiting proliferation of various cancer cell lines providing evidence of utility of Ml 1 in treatment or prophylaxis of cancer, particularly retinoblastoma, breast cancer, melanoma, adrenal carcinoma, cervical cancer, osteosarcoma, and lung cancer. Ml 1 is also effective in increasing survival after anoxia in neurons providing evidence of utility of Ml 1 in treatment or prophylaxis of ischemia, particularly of the brain and CNS.
  • M21 is effective in inhibiting proliferation of a retinoblastoma cell line providing evidence of utility of M21 and related compounds in treatment or prophylaxis of cancer, particularly retinoblastoma.
  • M21 is broadly effective in increasing survival after anoxia in various tissues providing evidence of utility of M21 and related compounds in treatment or prophylaxis of ischemia particularly of the CNS, brain, liver, heart and retina.
  • M21 and related compounds are also effective for treatment or prophylaxis of pain or glaucoma.
  • the agents and compositions of the invention are useful for in treatment or prophylaxis of a variety of diseases and manufacture of a medicament for such purposes as described below and elsewhere herein, particularly neurological diseases, and especially diseases mediated in part by ischemia.
  • the agents and compositions are also effective for treatment or prophylaxis of cancer and pain.
  • the method are useful in treating subjects in which sign(s) and/or symptom(s) of disease are already present or in prophylaxis of subjects without known symptom(s) of disease but at enhanced risk of developing symptoms by virtue of one or more risk factors associated with the disease.
  • Risk factors can be for example, genetic, biochemical or environment. Risk factors can also occur because the subject is about to undergo an event that carriers a known predisposition to development of disease (e.g., cardiac or brain surgery predisposes to development of ischemia).
  • ischemic or neurodgenerative nervous system injuries such as stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, dementia, epilepsy, spinocerebellar ataxia, spinal and bulbar muscular dystrophy, dentatorubropallidoluysian atrophy, brain injury, spinal cord injury, and other traumatic, ischemic or neurodgenerative nervous system injuries, or pain.
  • Non-neurological diseases including ischemic and degenerative disorders and conditions of other tissues, such as those of the heart, liver, kidneys, muscles, retina, skin, intestines, pancreas, gall bladder, thyroid, thymus, spleen, bone, cartilage, joints, lungs, diaphragm, adrenal glands, salivary, lacrimal glands, blood vessels and cells of endodermal, mesodermal and ectodermal origin.
  • Other disease and conditions are optical disorders, such as glaucoma, diabetic retonipaty, and macular degeneration.
  • cancers treatable by the disclosed compounds include breast cancer, adrenal carcinoma, cervical cancer, osteosarcoma, lung cancer (small cell and nonsmall cell), colon cancer, renal cancer, retinoblastoma, head and neck cancers, gastric cancer, melanoma, ovarian cancer, endometrial cancer, prostate cancer, pancreatic cancer, esophageal cancer, hepatocellular carcinoma (liver cancer), mesothelioma, sarcomas, and brain tumors (e.g., gliomas, such as glioblastomas), leukemia and lymphoma.
  • gliomas such as glioblastomas
  • TRPM7 Other disease amenable to treatment include autoimmune disorders and under undesired immune response, arrhythmia, depressive disorders, stress disorders, bone formation (using activators of TRPM7).
  • Evidence supporting a role of TRPM7 in various types of cancer is provided by Guilbert, Am. J. Cell. Phys. 257, C943-501 (2009 (breat cancer); Hanaro. J. Pharmacol. Sci. 95, 403-419 (2004) (retinoblastoma); Jian, Cancer Cell. Res. 67, 10929-10938 (2007) (head and neck cancer); Kim, Cancer Sci.99, 2502-2509 (2008) (gastric cancer); McNeil, J. Invest. Derm.
  • TRPM7 has also been implicated in hypertension(Trouyz, Am. J. Physiol. Heart Circ. Physiol. 294: HI 103-H1118 (2008)), myocardial fibrosis and heart failure.
  • the term "disease” includes pain.
  • the agents described herein e.g., TRPM7 modulators, can be used in treatment or prophylaxis of pain.
  • pain refers to an experiential phenomenon that is highly subjective to the individual experiencing it, and is influenced by the individual's mental state, including environment and cultural background.
  • Physical pain can usually be linked to a stimulus perceivable to a third party that is causative of actual or potential tissue damage. In this sense, pain can be regarded as a "sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage," according to the International Association for the Study of Pain (IASP).
  • IASP International Association for the Study of Pain
  • some instances of pain have no perceivable cause. For example, psychogenic pain, including exacerbation of a pre-existing physical pain by psychogenic factors or syndromes of a sometimes-persistent, perceived pain in persons with psychological disorders without any evidence of a perceivable cause of pain.
  • Pain includes nociceptive pain, neuropathic/neurogenic pain, breakthrough pain, allodynia, hyperalgesia, hyperesthesia, dysesthesia, paresthesia, hyperpathia, phantom limb pain, psychogenic pain, anesthesia dolorosa, neuralgia, neuritis.
  • Other categorizations include malignant pain, anginal pain, and/or idiopathic pain, complex regional pain syndrome I, complex regional pain syndrome II. Types and symptoms of pain need not be mutually exclusive. These terms are intended as defined by the IASP.
  • Nociceptive pain is initiated by specialized sensory nociceptors in the peripheral nerves in response to noxious stimuli, encoding noxious stimuli into action potentials.
  • Nociceptors generally on ⁇ - ⁇ and C fibers, are free nerve endings that terminate just below the skin, in tendons, joints, and in body organs.
  • the dorsal root ganglion (DRG) neurons provide a site of communication between the periphery and the spinal cord. The signal is processed through the spinal cord to the brainstem and thalamic sites and finally to the cerebral cortex, where it usually (but not always) elicits a sensation of pain.
  • Nociceptive pain can result from a wide variety of a chemical, thermal, biological (e.g., inflammatory) or mechanical events that have the potential to irritate or damage body tissue, which are generally above a certain minimal threshold of intensity required to cause nociceptive activity in nociceptors.
  • chemical, thermal, biological (e.g., inflammatory) or mechanical events that have the potential to irritate or damage body tissue, which are generally above a certain minimal threshold of intensity required to cause nociceptive activity in nociceptors.
  • Neuropathic pain is generally the result of abnormal functioning in the peripheral or central nervous system, giving rise to peripheral or central neuropathic pain, respectively.
  • Neuropathic pain is defined by the International Association for the Study of Pain as pain initiated or caused by a primary lesion or dysfunction in the nervous system.
  • Neuropathic pain often involves actual damage to the nervous system, especially in chronic cases.
  • Inflammatory nociceptive pain is generally a result of tissue damage and the resulting inflammatory process.
  • Neuropathic pain can persist well after (e.g., months or years) beyond the apparent healing of any observable damage to tissues.
  • neuropathic pain examples include tactile allodynia (e.g., induced after nerve injury) neuralgia (e.g., post herpetic (or post-shingles) neuralgia, trigeminal neuralgia), reflex sympathetic dystrophy/causal gia (nerve trauma), components of cancer pain (e.g., pain due to the cancer itself or associated conditions such as inflammation, or due to treatment such as chemotherapy, surgery or radiotherapy), phantom limb pain, entrapment neuropathy (e.g., carpal tunnel syndrome), and neuropathies such as peripheral neuropathy (e.g., due to diabetes, HIV, chronic alcohol use, exposure to other toxins (including many chemotherapies), vitamin deficiencies, and a large variety of other medical conditions).
  • tactile allodynia e.g., induced after nerve injury
  • neuralgia e.g., post herpetic (or post-shingles) neuralgia, trigeminal neuralgia
  • Neuropathic pain includes pain induced by expression of pathological operation of the nervous system following nerve injury due to various causes, for example, surgical operation, wound, shingles, diabetic neuropathy, amputation of legs or arms, cancer, and the like.
  • Medical conditions associated with neuropathic pain include traumatic nerve injury, stroke, multiple sclerosis,
  • a pain-causing stimulus often evokes an inflammatory response which itself can contribute to an experience of pain.
  • pain appears to be caused by a complex mixture of nociceptive and neuropathic factors.
  • chronic pain often comprises inflammatory nociceptive pain or neuropathic pain, or a mixture of both.
  • An initial nervous system dysfunction or injury may trigger the neural release of inflammatory mediators and subsequent neuropathic inflammation.
  • migraine headaches can represent a mixture of neuropathic and nociceptive pain.
  • myofascial pain is probably secondary to nociceptive input from the muscles, but the abnormal muscle activity may be the result of neuropathic conditions.
  • the agents discussed herein can alleviate or prevent at least one symptom of pain. Symptoms of pain experienced by a patient may or may not be accompanied by signs of pain discernable to a clinician. Conversely, pain can be manifested by clinical signs without the patient being aware of symptoms.
  • Symptoms of pain can include a response to pain, e.g., in the form of a behavioural change.
  • exemplary responses to pain can include conscious avoidance of a painful stimulus, a protective response intended to protect the body or body parts from the painful stimulus, responses intended to minimize pain and promote healing, communication of pain, and physiological responses.
  • Communicative responses can involve vocalizations of pain or modifications of facial expression or posture.
  • Physiological responses are include responses mediated by the autonomic nervous system or endocrine system, e.g., enhanced release of adrenalin and noradrenalin, increased output of glucagon and/or hormones and/or corticosteroids.
  • Physiological changes that can be monitored include locomotor effects such as twitching, convulsions, paralysis, dilated pupils, shivering, hyperesthesia and/or altered reflexes.
  • Physiological cardiovascular responses to pain can include changes in blood pressure, alterations in pulse rate and quality, decreased peripheral circulation, cyanosis and congestion.
  • Increased muscle tension is also symptomatic of pain. Changes in brain function in response to pain can be monitored by various techniques such as
  • EEG electroencephalography
  • FEMG frontal electromyography
  • PET positron emission tomography
  • pain Another symptom of pain can be referred pain, which is a perception of pain as being localized at a site adjacent to or at a distance from the actual site of the pain- causing stimulus.
  • referred pain arises when a nerve is compressed or damaged at or near its origin. In this circumstance, the sensation of pain is generally felt in the territory that the nerve serves, even though the damage originates elsewhere.
  • a common example occurs in intervertebral disc herniation, in which a nerve root arising from the spinal cord is compressed by adjacent disc material.
  • pain may arise from the damaged disc itself, pain is also felt in the region served by the compressed nerve (for example, the thigh, knee, or foot).
  • Nociceptive activity is a symptom of nociceptive pain. Nociceptive activity, even in the absence of consciously-perceived pain, may trigger withdrawal reflexes and a variety of autonomic responses such as pallor, diaphoresis, bradycardia, hypotension, lightheadedness, nausea and fainting.
  • One patient class amenable to treatments are patients undergoing a surgical procedure that involves or may involve a blood vessel supplying the brain, or otherwise on the brain or CNS. Some examples are patients undergoing cardiopulmonary bypass, carotid stenting, diagnostic angiography of the brain or coronary arteries of the aortic arch, vascular or endovascular surgical procedures and neurosurgical procedures.
  • Patients with a brain aneurysm are particularly suitable. Such patients can be treated by a variety of surgical procedures including clipping the aneurysm to shut off blood, or performing endovascular surgery to block the aneurysm with small coils or introduce a stent into a blood vessel from which an aneurysm emerges, or inserting a microcatheter. Endovascular procedures are less invasive than clipping an aneurysm but the outcome still includes a high incidence of small infarctions.
  • the agents of the invention can be formulated and administered in the form of a pharmaceutical composition.
  • An agent included in such a composition is typically substantially pure of contaminants (i.e., contaminants resulting from production of an agent including synthesis and/or purification).
  • contaminants i.e., contaminants resulting from production of an agent including synthesis and/or purification.
  • an agent can be at least 75, 90, 95 or 99% w/w free of such contaminants.
  • substantial freedom from contaminants does not preclude the agent being formulated with one or more
  • compositions are manufactured under GMP conditions.
  • compositions can be provided in unit dosage form (i.e., the dosage for a single administration).
  • a pill, capsule or the like can provide a single oral dose and a vial can provide a single dose for parenteral administration.
  • Pharmaceutical compositions can be manufactured by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • compositions can be formulated in conventional manner using one or more pharmaceutically acceptable carriers (including diluents, excipients or other auxiliaries) that facilitate processing, storage or administration of agents. Proper formulation is dependent on the route of administration chosen.
  • Administration can be parenteral, intravenous, oral, subcutaneous, intraarterial, intracranial, intrathecal, intraperitoneal, topical, intranasal or intramuscular.
  • compositions for parenteral administration are preferably sterile and substantially isotonic.
  • agents can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline or acetate buffer (to reduce discomfort at the site of injection).
  • physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline or acetate buffer (to reduce discomfort at the site of injection).
  • the solution can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • agents can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • a suitable vehicle e.g., sterile pyrogen-free water
  • penetrants appropriate to the barrier to be permeated are used in the formulation. This route of administration can be used to deliver the compounds to the nasal cavity or for sublingual administration.
  • agents can be formulated with pharmaceutically acceptable carriers as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
  • suitable excipients include fillers such as sugars, such as lactose, sucrose, mannitol and sorbitol; cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium
  • disintegrating agents can be added, such as the cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • solid dosage forms can be sugar-coated or enteric-coated using standard techniques.
  • suitable carriers, excipients or diluents include water, glycols, oils, alcohols. Additionally, flavoring agents, preservatives, coloring agents and the like can be added.
  • the agents can also be formulated as a depot preparation. Such long acting formulations can be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the agents can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • Liposomes and emulsions can be used to deliver agents.
  • Certain organic solvents such as dimethylsulfoxide also can be employed, although usually at the cost of greater toxicity.
  • the compounds can be delivered using a sustained-release system, such as semipermeable matrices of solid polymers containing the therapeutic agent.
  • Sustained-release capsules can, depending on their chemical nature, release the chimeric peptides for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization can be employed.
  • Agents can be formulated as free acids or bases or as pharmaceutically acceptable salts (see generally Berget al, 66 J. PHARM. SCI. 1-19 (1977), and C.G. Wermuth and P.H.Stahl (eds.) "Pharmaceutical Salts: Properties, Selection, and Use" Verlag Helvetica Chimica Acta, 2002 [ISBN 3-906390-26-8].
  • Pharmaceutically acceptable salts are those salts which substantially retain the biologic activity of the free bases and which are prepared by reaction with inorganic acids. Pharmaceutical salts tend to be more soluble in aqueous and other protic solvents than are the corresponding free base forms.
  • Pharmaceutically acceptable acid salts include hydrochloride,
  • Suitable base salts include aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, and diethanolamine salts
  • the agents are used in a regime (i.e., dose, frequency, route of administration) effective to achieve the intended purpose (e.g., reduction of damage effect of ischemia).
  • a therapeutically effective regime means a regime that reduces or at least inhibits further deterioration of at least one symptom or sign of disease in a population of patients (or animal models) treated with the agent relative to a control population of patients (or animal models) not treated with the agent.
  • Signs and symptoms of disease include infarctions (in the case of ischemic diseases), delayed neuronal death, and cognitive deficits, e.g., in memory, in ischemic and other neurologic disease, and reduced proliferation, toxicity and/or metastasis for cancer.
  • the regime is also considered therapeutically effective if an individual treated patient achieves an outcome more favorable than the mean outcome in a control population of comparable patients not treated by methods of the invention.
  • a regime is also considered therapeutically effective if an individual treated patient shows a disability of two or less on the Rankin scale and 75 or more on the Barthel scale.
  • a regime is also considered therapeutically effective if a population of treated patients shows a significantly improved (i.e., less disability) distribution of scores on a disability scale than a comparable untreated population, see Lees et at 1., N Engl J Med 2006;354:588-600.
  • a prophylactically effective regime means a regime that delays the onset, reduces the frequency of onset, and/or reduces severity of at least one sign or symptom of disease in a population of patients (or animal models) treated with the agent relative to a control population of patients (or animal models) not treated with the agent.
  • An effective regime refers to a regime that is effective therapeutically, prophylactically or both.
  • the amount of agent administered depends on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.
  • the therapy can be repeated intermittently while symptoms detectable or even when they are not detectable.
  • the therapy can be provided alone or in combination with other drugs.
  • Therapeutically effective dose of the present agents can provide therapeutic benefit without causing substantial toxicity.
  • Toxicity of the chimeric peptides can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by determining the LD50 (the dose lethal to 50% of the population) or the LD100 (the dose lethal to 100% of the population). The dose ratio between toxic and therapeutic effect is the therapeutic index. Chimeric peptides or peptidomimetics exhibiting high therapeutic indices are preferred (see, e.g., Fingl et al, 1975, In: The Pharmacological Basis of Therapeutics, Ch.l, p. l).
  • An assay for screening for a bioactive agent that modulates TRPM7 activity be created in which TRPM7 activity is evoked in cells, and then a bioactive agent that inhibits TRPM7 activity is tested to determine whether or not it prevents cell death in the assay.
  • the cell may be expressing native (wild-type) TRPM7, or a recombinant TRPM7 which is transfected into the cell.
  • human embryonic kidney (HEK293 Trex) cells were stably transfected with a tetracycline inducible Flag-tagged TRPM7 construct.
  • TRPM7 ionc channel activity may be increased by lowering extracellular divalent cation concentrations, especially Ca2+ and Mg2+ (Wei et al., 2007). This causes a marked increase in the ionic current carried by TRPM7 channels ( Figure 17 A-G). Tet-induced TRPM7-expressing HEK293 cells that are exposed to a reduction in divalent undergo spontaneous TRPM7-activity-mediated cell death over a 24-48 hour period ( Figure 17H) . This cell death can be measured, and the impact of a candidate TRPM7 modulator on this cell death can be measured.
  • Exemplary assays that can be used for measuring cell death induced by TRPM7 activity include an assay for measuring lactate dehydrogenase (LDH), which is released from dying cells and an assay for measuring ATP in living cells, such as the CellTiter Glo kit® from Promega. Cell death can also be measured by fluorescent measurements of propidium iodide and dihydrorhodamine.
  • LDH lactate dehydrogenase
  • Tet-inducible Flag-murine TRPM7/pCDNA4-TO HEK293 Trex cells are cultured in : MEM (invitrogen) supplemented with 10% fetal bovine serum, 20mM GlutaMAX-1, lOOunits/ml penicillin G sodium, 100 units/ml streptomycin
  • HBSS Hank's Balanced Salt Solution
  • Mg2+- deficient HBSS used to activate TRPM7 contains: (in mM): 121 NaCl, 5 KCl, 20 D-glucose, 10 HEPES acid, 10 HEPES-Na, 1.8 CaC12,l Na-pyruvate( all from Sigma) Stably Transfected Flag-Tagged TPM7 HE 293 Trex Cells
  • a HEK-293 cell line with a tetracycline-controlled expression of a Flag-tagged TRPM7 construct is used in the current example (Flag-murine TRPM7/pCDNA4-TO; (Aarts et al, 2003)).
  • Stably transfected Flag-murine TRPM7/pCDNA4-TO HEK293 Trex cells are thawed from frozen stock kept in liquid nitrogen, and cultured in culture medium for 5 days in 100 mm dishes (Costa). After the 5th day, they are trypsinized with 0.05% Trypsin (invitrogen) for 5 min and then split into two 100 mm dishes, cultured for another 4-5 days, then trypsinized again as above and seeded into multi 96-well plates at 4-5xl04/well/100ul, or 384-well plate at 1.3-1.5x104 Cells/well/40ul. Cells used in the present experiments are kept to three passages or less.
  • the cells are maintained at 37oC with 5% C02 in a humidified incubator. All culture plates and multi-well plates (Costa) are coated with poly-D-lysine .
  • the coating with poly-D-lysine is performed using 0. lmg/ml poly-D-lysine (P1045 Sigma) for 12h at 37C, followed by four washes with sterilized D-PBS (invitrogen) without MgC12 and CaC12.).
  • LOP AC 1280TM a library of 1280 pharmacologically-active compounds (Sigma, Prod. No. LO1280)
  • the Prestwick Chemical Library® (Prestwick Chemical) contains 1120 small molecules, 90%> being marketed drugs and 10%> bioactive alkaloids or related substances.
  • the active compounds were selected for their high chemical and pharmacological diversity as well as for their known bioavailability and safety in humans.
  • the Maybridge Screening collection consisting of 53,000 organic compounds with drug-like properties that generally obey Lipinski's "rule of five" (Lipinski et al., 2001) and so demonstrate good ADME (absorption, distribution, metabolism and excretion) profiles.
  • the test compounds were plated in 96 or 384 well formats, and initially used at a concentration of: 4uM for compounds of the LOP AC library and 5uM for each of the Prestwick and Maybridge libraries.
  • the compounds were used at concentrations ranging from 39 nM to 20 uM (obtained by performing two-fold serial dilutions 39nM, 78nM, 156nM, 315nM, 625nM, 1.25uM, 2.5uM, 5uM, lOuM, 20uM).
  • B score is a relative potency score based on the raw sample PI fluorescence value. They are the ratio of an adjusted raw PI fluorescence value in the numerator to a measure of variability in the denominator. Details are provided by Brideau et al. (Supra).
  • fraction DEAD (Ft - Fo)/Fmax
  • Ft PI fluorescence of the sample at time t
  • Fo initial PI fluorescence
  • Fmax background subtracted PI fluorescence the same cultures after exposure to lOOuM triton-X.
  • Tet-induced flag- murine TRPM7/pCDNA4-TO HEK293 Trex cells exhibit more cell death in 0% C02 than when they are kept in a 5% C02 environment ( Figure 18). Notably, there were no differences in cell death between cells kept in 0% vs 5% C02 in the presence of MgC12.
  • test compounds were loaded into the 96 well or 384 well plates containing the cells using a MultimekTM 96/384 channel automated pipettor (Beckman) at the same time as Tet induction or 24h after Tet induction as described above. Thereafter, the cells were incubated in Mg2+- containing, or Mg2+-deficient HBSS in order to activate TRPM7 channels.
  • the HBSS also contains lOug/ml of propidium iodide (PI;Molecular Probes Inc), a fluorescent cell viability indicator.
  • PI propidium iodide
  • Negative control was the Tet-induced TRPM7-HEK cells in HBSS buffer.
  • Positive control was the Tet-induced TRPM7-HEK cells in Mg-deficient HBSS buffer.
  • the Maybridge Screening collection consisting of 53,000 organic compounds with drug- like properties. These are screened in 384 well plates using the HTS approach described above.
  • H9c2 As a model of cardiac ischemia and reperfusion, a rat ventricular myoblast cell line H9c2 is used (Kimes and Brandt, 1976). H9c2 cells are morphologically similar to embryonic cardiocytes and possess several characteristics of the electrical and hormonal signal pathways found in adult cardiac cells (Hescheler et al., 1991).
  • This cell line has previously been used in cardiac research (Levrand et al, 2006; Zordoky and El-Kadi, 2007), and more importantly, in culture models of myocyte ischemia and reperfusion (Sakamoto et al, 1998; Ekhterae et al, 1999; Bonavita et al, 2003; Fiorillo et al, 2006; Coaxum et al, 2007).
  • the rat cardiomyoblast cell line H9c2 was obtained from the American Type Culture Collection (CRL-1446) and cultured in Dulbecco's Modified Eagle Medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum and 1% antibiotic- antimycotic. Cells were grown in an atmosphere of 95% 02/5% C02 in a humidified incubator.
  • TRIzol reagent Invitrogen, Burlington, ON, Canada
  • One ⁇ g of isolated RNA is reverse-transcribed using the High Capacity cDNA Archive Kit (Applied Biosystems, Streetsville, ON, Canada) and PCR is carried out using REDTaq DNA polymerase (Sigma, Oakville, ON, Canada) and the following rat TRPM7-specific primers:
  • PCR reactions were cycled for 5 mins at 94°C, followed by 30 cycles of 94°C for 1 min, 57°C for 30 sec, 72°C for 45 sec, and 72°C for 10 mins. PCR products were separated on a 1% agarose gel stained with ethidium bromide and visualized under UV light.
  • Oxygen Glucose Deprivation OGD
  • H9c2 cells were made anoxic by replacing the medium with de-oxygenated Ischemic buffer (in mM: 1.13 CaCl 2 , 5 KC1, 0.3 KH 2 P0 4 , 0.5 MgCl 2 , 0.4 MgS0 4 , 128 NaCl, 10 HEPES) and by transferring themto an anaerobic chamber (5% C0 2 , 10% H 2 , 85% N 2 ) for 6 hrs or 16 hrs at 37°C.
  • de-oxygenated Ischemic buffer in mM: 1.13 CaCl 2 , 5 KC1, 0.3 KH 2 P0 4 , 0.5 MgCl 2 , 0.4 MgS0 4 , 128 NaCl, 10 HEPES
  • OGD was terminated by washing the cells with oxygenated glucose-containing Control buffer (in mM: 1.13 CaCl 2 , 5 KC1, 0.3 KH 2 P0 4 , 0.5 MgCl 2 , 0.4 MgS0 4 , 128 NaCl, 10 HEPES 10 Glucose). Cultures were maintained for another 2hrs at 37°C in a humidified 5% CO 2 atmosphere. Normoxic cells were maintained in Control buffer for the duration of the experiment.
  • oxygenated glucose-containing Control buffer in mM: 1.13 CaCl 2 , 5 KC1, 0.3 KH 2 P0 4 , 0.5 MgCl 2 , 0.4 MgS0 4 , 128 NaCl, 10 HEPES 10 Glucose.
  • TRPM7 niRNA is detectable in most tissues examined in mouse and rat, including mouse and rat hearts.
  • TRPM7 mRNA was also detectable in H9c2 cells ( Figure 23).
  • TRPM7 protein was detectable in the H9c2 cells by immunochemistry ( Figure 24), indicating that this myocardial cell line is appropriate for studying TRPM7-mediated anoxic damage in myocardial cells.
  • TRPM7 is present in H9c2 cells, that these cells are vulnerable to cell death induced by OGD, and that this can be reduced by procedures that inhibit TRPM7.
  • the data implicate TRPM7 as a factor in ischemic death of cardia myocites.
  • the TRPM7 channel provides a pathway for mono- and divalent cations into the cell, and is unique in that it contains a functional C-terminal a-kinase domain.
  • the TRPM7 channel has been shown to be activated by chemical anoxia using NaCN (Aarts et al., 2003) .
  • the induction of chemical anoxia in host cells such as recombinant HEK293 cells can be used to activate TRPM7.
  • This activation is detectable with the use measurements of cellular calcium accumulation. This is achievable with the use of a fluorescent calcium indicator.
  • this activation can also be measured using radiolabeled Ca2+ ( 45 Ca 2+ ) as described previously by Sattler et al. (Sattler et al, 1998) and Aarts et al. (Aarts et al, 2003).
  • the TRPM7 construct was a Flag-TRPM7/pBluescript II KS construct ( Figure 27).
  • the Flag-TRPM7 cDNA is comprised of the murine TRPM7 sequence (GenBank accession no. AY032591)) conjugated to a Flag epitope tag at its N-terminus, and was subcloned into the pBluescript vector from a Flag-TRPM7/pcDNA4/TO construct (Aarts et al., 2003). Restriction enzyme digest with EcoRI determined the direction of insert in the pBluescript vector.
  • Figure 27 illustrates that the banding pattern observed corresponded to a 3' ⁇ 5' direction of insert (in bps): 3838, 3200, and 1592.
  • TRPM7 sequence was subcloned into a modified pTracer-CMV2 vector (Promega, Madison WI) ( Figure 28). This vector had been modified such that the GFP cDNA of the original was replaced by enhanced GFP (eGFP) cDNA.
  • eGFP enhanced GFP
  • the Flag-TRPM7/pTracer-CMV2 construct was generated by ligating the 5745bp fragment of a Spel/Kpnl digest of Flag-TRPM7/pBluescript with the 6140bp fragment of a Kpnl/Xbal digest of pTracer, ensuring that the Flag tag is preserved through the subcloning and that the TRPM7 sequence is inserted into the pTracer vector in the correct orientation (5' ⁇ 3') for expression. Selected transformants were screened by restriction enzyme digest with EcoRI, then with EcoRV, Pmel, and BamHI.
  • HEK-293 tSA (HEK-293T) cells were cultured in Dulbecco's Modified Eagle Medium with L-glutamine and sodium pyruvate (DMEM; Gibco, Burlington, ON), supplemented with 10% fetal bovine serum (FBS; Gibco) and 1% antibiotic-antimycotic (Gibco) on polystyrene cell culture dishes (Sarstedt, Montreal, QC). Cells were maintained in a humidified incubator (Steri-Cycle® C02 incubator, model 370; Thermo Electron Corp.) set at 37°C and 5% C02. Media was replaced routinely in 60mm and 35mm dishes with 5mL and 2mL respectively. When cells reached 75-90%) confluency, as estimated under a light microscope (NIKON Diaphot-TMD; Nikon Canada,
  • Transient transfections were performed at 75% confluency, as estimated under a light microscope (NIKON Diaphot-TMD; Nikon Canada), using Lipofectamine 2000 (Invitrogen). Transfections were performed according to the manufacturer's instructions. For a 35mm cell culture dish, 3 ⁇ g of DNA and ⁇ .5 ⁇ ⁇ of Lipofectamine (a 1 :2.5 ratio of DNA to reagent) was diluted in 500 ⁇ OptiMEM® I reduced serum medium (Gibco). Media was replaced no sooner than 16 hours post-transfection.
  • Transfection efficiency (%) no. of eGFP-expressing cells / no. of Hoechst stained cells x 100.
  • Hoechst 33342 was purchased as a lOmg/mL solution in water (Molecular Probes Inc., Eugene, OR). Propidium iodide (PI) was purchased as a powder and prepared by dissolving in PBS at lmg/mL. PI solutions were stored at 4°C until use. Hoechst and PI were added directly to cell culture to 5 ⁇ g/mL and 10 ⁇ g/mL respectively. Cells were incubated at room temperature or at 37°C for 10 minutes to allow for adequate uptake, and fluorescence observed using a NIKON Eclipse TE2000 inverted microscope and TE-FM Epi-Fluorescence attachment (Nikon Canada).
  • Frosty" freezing container Naalgene at -80°C (Forma -86C ULT freezer, Thermo Electron Corp.) for at least 2 hours.
  • the contents of the container when filled with isopropanol, experience a cooling rate of 1°C per minute.
  • Cells were transferred to a -140°C liquid nitrogen freezer (Cryoplus 1, Forma Scientific) for long-term storage.
  • Poly-D-lysine (mw > 300,000; Sigma-Aldrich) was purchased in its lyophilized powder form and stored at -20°C until use.
  • poly-D-lysine was diluted in water at O.lmg/mL and 250 ⁇ dispensed into each well. Plates were incubated at 37°C in a humidified incubator for at least 4 hours, the solution aspirated, wells washed twice with water, and allowed to dry. Coated plates were stored at 4°C for up to three months.
  • Fluo-3 was purchased from Molecular Probes Inc. in its acetoxymethyl (AM) ester form. A 5mM fluo-3 AM stock was prepared in DMSO and stored at -20°C for up to several days. Pluronic® F-127 was purchased as a 10% solution in water (Molecular Probes Inc.).
  • a loading solution containing 5 ⁇ fluo-3 AM and 0.02% pluronic in a HEPES buffered salt solution (HBSS; 121mM NaCl, 5mM KC1, 20mM D-glucose, lOmM HEPES acid, lOmM HEPES-Na salt, 3mM NaHC0 3 , ImM Na-pyruvate, and 1.8mM CaCl 2 , pH adjusted to 7.4 with NaOH) was prepared by brief vortex followed by sonication (FS5; Fisher Scientific) for at least 2 minutes. Cells were washed with HBSS, loaded with fluo-3 AM by incubation at 37°C for 30 minutes, and washed again to remove excess dye. Fluo-3 fluorescence was visualized using a NIKON Eclipse TE2000 inverted microscope and TE-FM Epi-Fluorescence attachment (Nikon Canada) or measured using a Fluoroskan Ascent FL microplate reader
  • ⁇ /pTracer construct were plated onto 24-well plates, 24-hours post-transfection. Untransfected cells were plated at 0.75xl0 6 cells/well and transfected cells at lxlO 6 cells/well. The plates were coated with poly-D-lysine to strengthen cell adhesion and to minimize cell loss during washes. Cells were loaded by incubation with 5 ⁇ fluo-3 AM and 0.02% pluronic in HBSS at 37°C for 30 minutes.
  • aglycaemic HBSS containing, in mM: 20 N-methyl-D-glucamine (NMDG), 121 NaCl, 5 KC1, 10 HEPES acid, 10 HEPES-Na salt, 3 NaHC0 3 , 1 Na- pyruvate, and 1.8 CaCl 2 , pH adjusted to 7.4 with HC1.
  • Calcium uptake as assessed by fluo-3 fluorescence, was measured in response to 0, 5, 10, 15, 20, or 25mM sodium cyanide (NaCN; Mallinckrodt Baker Inc., Phillipsburg, NJ) dissolved in aglycaemic HBSS.
  • NaCN sodium cyanide
  • a 250mM NaCN stock was prepared in water and stored at room temperature for up to 2 weeks. Measurements of fluo-3 fluorescence were taken over a 2 hour period at 10 minutes intervals at room temperature (22-25°C). Calcium uptake assays were performed 48 hours post-transfection.
  • Statistical analysis of data was carried out with a two-tailed Student's t test, or a one-way analysis of variance (ANOVA) followed by post hoc pairwise multiple comparisons testing using the Holm-Sidak method, where appropriate.
  • a Flag-TRPM7/pBluescript II KS construct ( Figure 27), containing the murine TRPM7 sequence (GenBank accession no. AY032591) conjugated to an in-frame N- terminal Flag epitope tag, was used as the basis for all manipulations in this project.
  • the full-length TRPM7 and APDZ sequences were subcloned into the pTracer-CMV2 eukaryotic expression vector, in which transgene expression is driven by the cytomegalovirus (CMV) promoter ( Figure 28).
  • the sequences were excised from their original pBluescript II KS cloning vectors and ligated with pTracer to generate the Flag-TRPM7/pTracer-CMV2 and Flag-APDZ/pTracer- CMV2 constructs (hereafter abbreviated to TRPM7/pTracer and APDZ/pTracer).
  • the pTracer vector contains cDNA for enhanced green fluorescent protein (eGFP), allowing for visual identification of transfectants. eGFP expression is driven by a separate EF-l promoter.
  • eGFP enhanced green fluorescent protein
  • the HEK-293 tSA (293T) cell line was selected for heterologous expression of the TRPM7 constructs by transient transfection.
  • Cells were transfected with one of the TRPM7/pTracer, or TRPM7/pTracereGFP-, constructs.
  • Cells transfected with the eGFP- containing construct were used in assessing transfection efficiency while cells transfected with the corresponding nonfluorescent construct were used in calcium uptake and cell death assays. Because calcium uptake and cell death assays were performed 48 hours post-transfection, transfection efficiency was also assessed at this time point.
  • Figure 29 illustrates the transfection efficiencies that were achieved with TRPM7/pTracer in the 293T cell line. Cells were counterstained with Hoechst 33342 to allow for simultaneous visualization of eGFP expression and of untransfected cells. Transfection efficiency was quantified by cell count and expressed as a percentage of the total number of cells.
  • TRPM7 constructs were loaded with fluo-3 AM and treated with 0, 5, 10, 15, 20, or 25mM sodium cyanide (NaCN) in a glucose-free HEPES buffered salt solution (HBSS; glucose substituted with an equimolar amount of N-methyl-D-glucamine (NMDG)) to simulate anoxia/aglycaemia.
  • HBSS glucose-free HEPES buffered salt solution
  • NMDG N-methyl-D-glucamine
  • TRPM7/pTracereGFP- showed significantly higher levels of [Ca2+]i than untransfected cells at the 10 and 15mM NaCN concentrations (Figure 30).
  • the fitted dose-response curves for NaCN-induced calcium uptake yielded an EC50 value of 17.6 ⁇ l .
  • TRPM7/pTracereGFP- showed significantly higher levels of [Ca2+]i than untransfected cells at 5, 10, and 15mM NaCN (Figure 31).
  • the fitted dose-response curves for TRPM7-transfected and for untransfected cells yielded EC50 values of 12.5 ⁇ l . lmM NaCN and 15.7 ⁇ 1.OmM NaCN respectively ( Figure 31).
  • Heterologous expression of the TRPM7 channel in 293T cells likely confers greater sensitivity to NaCN treatment, resulting in greater increases in intracellular Ca2+ levels than those observed in untransfected cells.
  • TRPM7/pTracereGFP- exhibited lower or similar levels of [Ca2+]i than untransfected cells.
  • PI uptake used as a measure of cell death, occurs when a cell exhibits compromised membrane integrity as in, for example, necrotic forms of cell death.
  • Compromised membrane integrity also allows the cleaved form of the fluo-3 AM ester to leak out of cells, thereby resulting in inaccurate measurements of intracellular Ca2+ levels.
  • the fluo-3 fluorescence measured at the 20 and 25mM NaCN concentrations may only represent [Ca2+]i in the subset of viable cells remaining, and as such may not be directly comparable to the fluorescence
  • PI propidium iodide
  • PI exhibits a 20- to 30-fold increase in fluorescence intensity upon associating with nucleic acids, and is commonly employed as an indicator of cell death.
  • Untransfected cells and cells transfected with the TRPM7/pTracereGFP- construct were stained with PI following a 2 hour NaCN treatment. The same cells were used in both the calcium uptake and cell death assays, such that PI uptake was assessed immediately after the last fluo-3 measurement at 2 hours. Cells were then exposed to 0.5% Triton X-100 to permeabilize all cell membranes, allowing for the quantification of maximal PI fluorescence as a measure of complete (100%) cell death to which all PI uptake values were subsequently normalized.
  • Figure 32 illustrates the levels of cell death that were observed at 2 hours of
  • a membrane translocation sequence/domain is coupled to a fragment of the small molecule, preferably but not exclusively at fragment E. If the small molecule terminates at fragments D, C, or B, then an MTD may be covalently attached to fragments D, C, or B, respectively.
  • the MTD may be coupled to the small molecule via an amide linkage, an ester linkage, a thioamide linkage or other form of covalent attachment. However, the MTD may not be attached to the P(0) carboxylate or phenyl since these functional groups are important modulating TRPM7 activity.
  • TRPM7 inhibitors identified in the TRPM7-dependent HEK death assay were tested for their ability to inhibit TRPM7 currents in cell systems.
  • Whole-cell patch clamp recordings were used essentially as described to test the TRPM7 inhibitors in HEK293 cells, H9c2 cardiomyocytes and cultured neurons. Each test compound was tested at 0.3, 1, 3, 10 and 30 uM, or as high as solubility permits.
  • Figures 34-40 show the TRPM7 currents in HEK 293 cells expressing TRPM7.
  • Figure 34 shows the baseline TRPM7 shaped curve
  • Figures 35-40 show the effect of extracellular application of TRPM7 inhibitors M5, M6, M7, Ml 1, M14 and M21. Results were similar for other cell lines.
  • TRPM7 inhibitors reduces current through the TRPM7 channel, with Mi l and M21 showing the highest level of inhibition.
  • TRPM7 is a large membrane protein that interacts with a number of other proteins and which contains a kinase domain.
  • inhibition of channel activity is not a requisite activity for a TRPM7 inhibitor, and indeed some of the inhibitors identified in the HEK293 TRPM7-dependent death assay increase survival but do not appear to block TRPM7 currents at the concentrations tested (data not shown).
  • M21 had no effect on agonist-induced Ca2+ changes in HEK293 cells transfected with constructs for TRPM2, TRPM4, TRPM6, TRPV1, TRPC2 and TRPA1. M21 also has no effect on NMD A and AMP A receptor currents in cultured neurons. Thus, at concentrations sufficient to inhibit TRPM7 channel activity, M21 does not appear to block other ion channels tested aside from potassium currents. Similar experiments were performed with other TRPM7 inhibitors including M5 and Mi l . Both also displayed slight inhibition of potassium currentsbut did not affect sodium or calcium currents. Thus, these results suggest that inhibition of TRPM7 itself is likely the mechanism for the protection from ischemia and anti-proliferative effects observed for TRPM7 inhibitors. They also suggest that these inhibitors are unlikely to display side effects due to the blockade of other currents/ion channels at concentrations that inhibit TRPM7 activity.
  • M21 and M6 were dissolved in DMSO at 10 mM as stock, then diluted into intracellular recording fluid (ICF) to final concentration of 2 mM. Immediately start recording of the TRPM7 like currents to RAMP change of membrane potentials after making the whole cell. Recording lasts for 10-20 minutes to compare the currents between control and test group. M21 and M6 applied
  • EXAMPLE 5 INHIBITION OF TRPM7 IN CELLS SUBJECTED TO OXYGEN AND GLUCOSE DEPRIVATION PROTECTS CELLS FROM DYING
  • TRPM7 Inhibition of TRPM7 has been described as a fundamental mechanism for the protection of neurons from anoxic damage (Aarts et al, 2003; Sun et al, 2008), which provides a wider time window of neuroprotection that other glutamate or L-type calcium channel inhibitors in models of anoxic damage to neurons.
  • This application discloses that TRPM7 is fundamental to anoxic/ischemic damage in all cell lineages and that inhibition of TRPM7 in tissues of all lineages provides protection from cell death following anoxia, as well as compounds for said inhibition.
  • TRPM7 is expressed in all cell lines and tissues tested to date by RT-PCR or western blot ( Figures 23, 24 and P).
  • Small molecules M5, M6, M7, Mil, M14 and M21 block anoxic death in murine primary neuronal cell cultures.
  • TRPM7 inhibitors were tested for their ability to reduce anoxic death in murine primary neuronal cell cultures subjected to 1 to 3 hours of OGD. This assay was generally performed as described by Aarts et al (2003). In brief, mixed cortical cultures enriched with neurons (85%) were prepared and used for experiments after 12-14 days in vitro. The cultures were transferred to an anaerobic chamber containing 5% C02, 10% H and 85%N2. Cultures were washed 3x with 500 ul deoxygenated glucose free bicarbonate solution and maintained anoxic for the appropriate duration at 37°C. OGD was terminated by washing the cultures with oxygenated glucose-containing bicarbonate solution, and the cultures were further maintained 1-24 hours in a humidified 5%C02 atmosphere. Cell death wash generally measured by fluorescence measurement of PI (50ug/ml) in a multiwall plate reader (CytoFluor II, Perseptive Biosystems).
  • Figure 69 shows that treatment of primary cultured mouse cortical cell cultures exposed to anoxic conditions with TRPM7 inhibitors can reduce the death associated with OGD in the presence or absence of MCN (a mixture of MK101, CNQX and Nimodipine to inhibit other glutamate channels).
  • Figure 69 shows that for M5, M6 and M21, protection of cultures from anoxic death is observed upon application of the TRPM7 inhibitor either prior to or following OGD.
  • Figures 55, 56 and 59 show that M5, M6 and M21 are able to provide protection to neuronal cultures following OGD.
  • TRPM7 inhibitors can provide protection even in cases where glutamate inhibitors are insufficient. This protection has been demonstrated for other TRPM7 inhibitors in this M series (M5, M6, M7, Ml 1, Ml 4 and M21). TRPM7 inhibitors can rescue cells from anoxic death in a large number of cell and tissue types.
  • TRPM7 inhibitors to protect other types of cell cultures following exposure to anoxia, including non-neuronal cell cultures.
  • cultures of growing cells are exposed to a 1-6 hour period of anoxia, followed by addition of a TRPM7 at a range of concentrations upon removal from anoxic conditions.
  • Figures 41-44 demonstrate the ability of M5, Mi l and M21 to promote survival of mixed retinal cell cultures ( Figures 42, 43), H9c2 cardiomyocytes ( Figure 44) and cultured ex vivo retinal explants (Figure 41) following exposure to OGD.
  • Figure 70 demonstrates that M5 and M21 can promote survival of hepatocyte cultures (AML12 cell line) exposed to either 2 hour, 4 hour or 6 hour anoxia.
  • Figure 71 demonstrates that M5, M6, Mi l and M21 can all promote survival of H9c2 cardiomyocytes after exposure to anoxia, and that the addition of luM Nifedipine, a calcium channel blocker used as an anti-anginal and anti-hypertensive medication, does not provide additional protection.
  • Figure 72 shows an additional example of the ability of M5 and M21 to promote survival of H9c2 cardiomyocytes exposed to anoxia, and demonstrates that the benefit is observed with either a 24 hour pre-treatment or post-treatment of the TRPM7 inhibitor M5.
  • TRPM7 inhibitors may be useful both as a treatment for anoxic damage to patients presenting symptoms of a disorder associated with anoxic damage, or as a preventative measure.
  • Such preventative measures can be chronic, such as treatment to protect against damage from heart attacks or strokes, or acute, to be given prior to or during surgical procedures, which may include but not be limited to procedures that involve endovascular invasion and have the possibility of dislodging material that may block blood flow through arteries.
  • preventative measures can include the reduction of anoxic damage associated with cardiovascular issues (heart attack, myocardial infarction, acute ischemic attacks, atrial fibrillation, etc), brain disorders (stroke, neurotrauma, etc), diabetic disorders (blindness, deafness, neuropathy), retinal/eye disorders (glaucoma, macular degeneration, blindness), aural disorders (deafness, progressive deafness, hearing loss), muscle disorders (weakness,
  • myodegenerative disease disorders associated with mitochondrial depletion
  • organ disorders kidney, lung, liver disorders associated with ischemia or anoxic damage
  • TRPM7 inhibitors are also shown herein to provide protection from anoxic damage in tissues.
  • Figures 73 and 75 show that treatment with TRPM7 inhibitors reduces cell death associated with myocardial infarction and glaucoma, respectively, as described in subsequent examples.
  • TRPM7 is a fundamental mechanism through which ischemia occurs. Blocking TRPM7 reduces anoxic damage in all cell and tissue systems tested, and appears to be a fundamental method for protecting cells against the effects of oxygen and glucose deprivation.
  • TRPM7 inhibitors are protective against anoxic damage in tissues derived from all tissue lineages (endodermal, mesodermal and ectodermal), including a wide range of differentiated cell types (neurons, fibroblasts, myocardial cells, hepatocytes, retinal ganglion cells, etc) and tissues (brain, heart, retina). Exemplary cells/tissue for each lineage in this invention include neurons/brain
  • TRPM7 ectodermal
  • heart cardiomyocytes
  • kidney meodermal
  • hepatocytes/liver endodermal
  • TRPM2 TRPM2, 3 and 6 levels varied among the tissues, but TRPM7 expression was ubiquitous and, consistent with previous reports, showed high levels in heart.
  • H9c2 ventricular myoblast cell line H9c2 cells are used extensively in studies of cardiac myocytes ischemia/reperfusion. Among the ischemic mechanisms elucidated to date are oxidative stress via ROS and reactive nitrogen species and the activation of pro-death signalling that parallel events triggered in neurons by TRPM7 activation. H9c2 cells exhibit TRPM7expression by RT-PCR ( Figure 23), Western blotting and by
  • M21 was applied as a single intravenous dose within 15 minutes of LAD occlusion.
  • Infarct volume evaluation was performed at 24h using routine methods. Treatment with M21 significantly reduced infarct volume across a range of doses as evaluated using triphenyl tetrazolium chloride (TTC; Figure 33). A more detailed evaluation of the infarcted tissue using TUNEL staining revealed that M21 treatment also significantly reduced the number of cells exhibiting DNA fragmentation ( Figure 73). These technological data confirm the feasibility of addressing myocardial cell death in-vivo by blocking TRPM7 with small molecule inhibitors. Thus, inhibitors of TRPM7 can be used to treat any afflictions of the heart that result in ischemic damage. These can include, but are not limited to, myocardial infarction (MI), Heart attack, acute ischemic attacks, and acute coronary disorders.
  • MI myocardial infarction
  • Heart attack Heart attack
  • acute ischemic attacks acute coronary disorders.
  • H9c2 cells were cultured and subjected to OGD as described supra.
  • Figure 71 panels A and B show the results of exposure to M21 or M5 for 24 hours following 6 hours of OGD.
  • Acute and chronic retinal ischemia are major causes of blindness.
  • Retinal damage from glaucoma also termed “slow excitotoxicity” afflicts millions of people each year and is the second leading cause of blindness worldwide (after cataracts).
  • Diabetic retinopathy is also very common, afflicting about 40% of diabetics and, while less commonly producing complete blindness, is a leading cause of visual impairment.
  • the retina is an extension of the CNS, and was the first organ in which excitotoxicity was described.
  • This invention discloses TPRM7 antagonists that can inhibit anoxic retinal damage. To examine this, we cultured primary retinal ganglion cells (RGCs) and organotypic whole retinas from neonatal rat pups by standard methods and exposed them to OGD (1 or 3 hours). Cell death was evaluated by PI fluorescence (shown) and by LDH release assays that showed similar results (not shown).
  • TRPM7 ischemic retinal cell death
  • these compounds are delivered orally, as an injection (intravenous, intraocular), or administered topically.
  • This model of glaucoma can be used to assess the different routes of administration for these compounds
  • TRPM7 inhibitors can reduce proliferation of cancerous cells under standard growth conditions when using Y79 retinoblastoma cells.
  • Treatment of these cells with 1-7.5 uM M6 resulted in the death of the cancer cells in 48-72 hours as measured by MTT assay ( Figure 76 panel A).
  • M6 is not toxic to either regular primary neurons in that concentration range (data not shown), or to NIH3T3 fibroblast cells ( Figure 82). This result was confirmed in a second retinoblastoma cell line (Weri cells), which also showed a similar dose response curve to M6 ( Figure 76 panel B).
  • TRPM7 inhibitors may be useful in the reduction of tumor metastasis in addition to either reducing the proliferation or killing of cancer cells.
  • Figure 78 is a repetition of the experiment, observing the distribution of Y79 cells after 12 days of migration off the retina. The darker bars of each pair indicate fluorescence intensity of cells that have migrated off of the retina. M6 treated cultures (1 uM) have significantly lower Y79 fluorescence off of the retinal explant.
  • TRPM7 Total protein was also isolated from all of the cell lines tested using standard methods and a western blot was performed using an anti-TRPM7 antibody. All cell lines displayed TRPM7 expression, suggesting that the TRPM7 inhibitors are acting through TRPM7 ( Figure 83).
  • siRNA was used as described previously to knock down expression of TRPM7 in B16F1 and B16F10 melanoma cell lines. Both cell lines showed a dose dependent reduction in proliferation in TRPM7 knock down samples when compared to scrambled siRNA controls (Fig. 84). Thus, blocking or eliminating TRPM7 is useful for the treatment of cancer.
  • m6 was selected to for a pilot evaluation of its ability to reduce tumor formation in a murine tumor model of B16F10 melanoma and a RXF-393 human renal cell carcinoma xenograft model of tumor proliferation.
  • a maximum tolerated dose study was performed that demonstrated M6 was tolerated in mice at concentrations up to the highest tested (20 mg/kg).
  • an appropriate number of cells were injected into the right flank ( ⁇ 3-5 million cells per animal in 0.1 ml 50% matrigel/50% media). When tumor sizes reached 100-150 mg, animals were randomized into control (vehicle only), positive control or M6.
  • M6 was given by intravenous injection to 20 mg/kg once daily. Tumors were measured and the weights were calculated by standard means.
  • Figure 85 shows the results of daily M6 injection on melanoma tumor growth. M6 reduces tumor growth in animals with active melanomas. A similar trend was observed in the renal cancer xenograft tumor formation model, further supporting that TRPM7 inhibitors have broad anti-proliferative activity across cancer types.
  • f test is the luminescent signal of the tested sample
  • f ve hicie is the luminescence of the vehicle in which the drug is dissolved (or appropriate measure for the other viability/proliferation measures).
  • X is the logarithm of concentration and Y is the response.
  • Y starts at the Bottom and goes to Top with a sigmoid shape.
  • TRPM7 Inhibition of TRPM7 with small molecule inhibitors reduce the proliferation of a wide range of cancers at non-toxic concentrations, and thus are effective anti-cancer agents for cancers arising from many different mechanisms. Similar to the role of TRPM7 in ischemia, the data suggest that TRPM7 plays a fundamental role in cancer cell proliferation, and that inhibition of TRPM7 provides an effective treatment for a wide range of cancers including all of those demonstrated herein.
  • TRPM7 inhibitors have been tested in a rodent model of formalin induced inflammatory pain. M21 treatment provided a statistically significant reduction in pain behaviors in rats after intravenous
  • Figure 68 demonstrates that the TRPM7 inhibitor M21 suppresses formalin-induced pain behaviors in rats with i.v. administration.
  • Figure 68 shows a time course of flinches induced by formalin (2.5%; 50 uL into the plantar hindpaw) with M21 or with saline as a negative control.
  • M21 significantly reduced formalin-induced phase 2 pain (9-60 min) but showed little effect at the concentrations tested in reducing phase 1 (0-8 min) flinches.
  • M21 and other TRPM7 inhibitors are able to treat pain. This model is indicative of both neuropathic and inflammatory pain, and thus would be suitable for the treatment of these types of pain in humans. It is likely that these inhibitors are effective in other types of pain as well. TABLE 1
  • compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the methods described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés de criblage de modulateurs de lésion de cellules de mammifères provoquée par l'activité du gène et de la protéine TRPM7, des composés qui modulent l'activité du gène et de la protéine TRPM7, et des méthodes de traitement de lésion de cellules de mammifères au moyen de modulateurs de l'activité du gène et de la protéine TRPM7 murins.
PCT/US2010/059976 2009-12-11 2010-12-10 Agents et méthodes de traitement de maladies ischémiques et d'autres maladies WO2011072275A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2010327936A AU2010327936B2 (en) 2009-12-11 2010-12-10 Agents and methods for treating ischemic and other diseases
JP2012543324A JP5848712B2 (ja) 2009-12-11 2010-12-10 虚血性疾患および他の疾患を治療するための薬剤および方法
CA2781888A CA2781888C (fr) 2009-12-11 2010-12-10 Agents et methodes de traitement de maladies ischemiques et d'autres maladies
EP10836790.5A EP2521724B1 (fr) 2009-12-11 2010-12-10 Agents et méthodes de traitement de maladies ischémiques et d'autres maladies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28595409P 2009-12-11 2009-12-11
US61/285,954 2009-12-11
US31215410P 2010-03-09 2010-03-09
US61/312,154 2010-03-09

Publications (2)

Publication Number Publication Date
WO2011072275A2 true WO2011072275A2 (fr) 2011-06-16
WO2011072275A3 WO2011072275A3 (fr) 2011-12-08

Family

ID=44146214

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/059976 WO2011072275A2 (fr) 2009-12-11 2010-12-10 Agents et méthodes de traitement de maladies ischémiques et d'autres maladies

Country Status (6)

Country Link
US (2) US8680137B2 (fr)
EP (1) EP2521724B1 (fr)
JP (3) JP5848712B2 (fr)
AU (1) AU2010327936B2 (fr)
CA (1) CA2781888C (fr)
WO (1) WO2011072275A2 (fr)

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012174488A2 (fr) 2011-06-15 2012-12-20 Nono, Inc. Agents et méthodes de traitement de maladies ischémiques et d'autres maladies
EP2578579A1 (fr) * 2010-07-14 2013-04-10 National Institute of Immunology Composés de carboxamide de benzothiophène, compositions et leurs applications
EP2733146A1 (fr) * 2012-11-20 2014-05-21 KTB Tumorforschungsgesellschaft mbH Dérivés de thioéther en tant qu'inhibiteurs de kinase de protéine
WO2014079545A1 (fr) * 2012-11-20 2014-05-30 Ktb Tumorforschungsgesellschaft Mbh Dérivés de thioéther utilisés en tant qu'inhibiteurs de protéines kinases
US8841487B2 (en) 2010-07-16 2014-09-23 Abbvie Inc. Phosphine ligands for catalytic reactions
WO2014121055A3 (fr) * 2013-02-04 2014-10-02 Janssen Pharmaceutica Nv Modulateurs flap
US8895737B2 (en) 2010-07-16 2014-11-25 Shashank Shekhar Process for preparing antiviral compounds
JP2014531402A (ja) * 2011-08-04 2014-11-27 ネオミクス カンパニー リミテッド 新規アニリン誘導体及びこれの用途（Ｎｏｖｅｌａｎｉｌｉｎｅｄｅｒｉｖａｔｉｖｅｓａｎｄｕｓｅｔｈｅｒｅｏｆ）
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
WO2015039333A1 (fr) * 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions en contenant et procédés correspondants
US9073876B2 (en) 2013-02-04 2015-07-07 Janssen Pharmaceutica Nv Flap modulators
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
US9296755B2 (en) 2013-01-25 2016-03-29 Glaxosmithkline Intellectual Property Development Limited 3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds and their therapeutic applications
WO2016077793A1 (fr) * 2014-11-14 2016-05-19 Children's Hospital Medical Center Inhibiteurs de sos1 pour le traitement du cancer
US9394287B2 (en) 2010-11-05 2016-07-19 Senomyx, Inc. Compounds useful as modulators of TRPM8
CN105829297A (zh) * 2013-12-20 2016-08-03 埃斯蒂文博士实验室股份有限公司 具有抗疼痛的多重模式活性的哌啶化合物
US9447039B2 (en) 2012-09-07 2016-09-20 Novartis Ag Indole carboxamide derivatives and uses thereof
EP2905278A4 (fr) * 2012-09-28 2016-11-09 Cristália Produtos Químicos Farmacêuticos Ltda Composés hétéroaromatiques, procédé de préparation de ces composé, compositions pharmaceutiques, utilisations et méthode de traitement des douleurs aiguë et chronique
US9566284B2 (en) 2009-12-11 2017-02-14 Nono Inc. Agents and methods for treating ischemic and other diseases
CN106565643A (zh) * 2016-10-31 2017-04-19 北京大学 D‑3‑磷酸甘油酸脱氢酶别构抑制剂及其应用
US9670163B2 (en) 2005-12-28 2017-06-06 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9670205B2 (en) 2015-03-04 2017-06-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
CN106822897A (zh) * 2017-02-17 2017-06-13 南京九寿堂医药科技有限公司 靶向下调trpm7基因表达在提高肺鳞癌化疗敏感性方面的应用
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US9732071B2 (en) 2015-10-01 2017-08-15 Senomyx, Inc. Compounds useful as modulators of TRPM8
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10214498B2 (en) 2014-10-24 2019-02-26 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10370342B2 (en) 2016-09-02 2019-08-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
EP3705570A1 (fr) 2014-02-10 2020-09-09 Institut Curie Utilisation de modulateurs mcoln-1 afin de réguler la migration cellulaire
US10919902B2 (en) 2015-07-06 2021-02-16 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11286257B2 (en) 2019-06-28 2022-03-29 Gilead Sciences, Inc. Processes for preparing toll-like receptor modulator compounds
WO2022119823A1 (fr) * 2020-12-04 2022-06-09 The Johns Hopkins University Composés et leur utilisation pour le traitement de la douleur neuropathique
CN114685371A (zh) * 2022-03-08 2022-07-01 四川大学 吡唑甲酰胺衍生物及其制备方法和用途
WO2022148781A1 (fr) 2021-01-05 2022-07-14 Institut Curie Association d'activateurs de mcoln et d'inhibiteurs de point de contrôle immunitaire
US11396509B2 (en) 2019-04-17 2022-07-26 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US11583531B2 (en) 2019-04-17 2023-02-21 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11780840B2 (en) 2020-07-02 2023-10-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
WO2024059524A1 (fr) * 2022-09-12 2024-03-21 Hotspot Therapeutics, Inc. Composés de pyrazolylcarboxamide et leur utilisation en thérapie
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101897881B1 (ko) 2008-01-04 2018-09-12 인텔리카인, 엘엘씨 특정 화학 물질, 조성물 및 방법
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2009288088B2 (en) * 2008-09-03 2014-12-04 Nono Inc. Agents and methods for treatment of pain
WO2011146882A1 (fr) 2010-05-21 2011-11-24 Intellikine, Inc. Composés chimiques, compositions et procédés pour modulation de kinases
EP2642998B1 (fr) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York Antagoniste rbp4 non rétinoïde pour le traitement de la dégénérescence maculaire liée à l'âge et de la maladie de stargardt
KR101875720B1 (ko) 2011-01-10 2018-07-09 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
KR20140063605A (ko) 2011-07-19 2014-05-27 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
AU2013216885B2 (en) * 2012-02-10 2017-08-03 The Board Of Regents Of The University Of Texas System Modulators of exchange proteins directly activated by cAMP (EPACs)
US9051299B2 (en) 2012-03-29 2015-06-09 Merck Sharp & Dohme Corp. Imidazolyl methyl piperidine T-type calcium channel antagonists
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN103570705B (zh) * 2012-07-18 2017-01-25 中国医学科学院医药生物技术研究所 取代的n‑((1＇,3＇‑杂唑‑4＇‑基)‑甲基)‑4‑苯甲酰基六氢吡啶类化合物及其用途
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
WO2014152018A1 (fr) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, leur préparation et leur utilisation
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
EP3137168B1 (fr) 2014-04-30 2022-01-05 The Trustees of Columbia University in the City of New York 4-phénylepipéridines substituées, leur préparation et utilisation
US20170273922A1 (en) * 2014-10-03 2017-09-28 The Royal Institution For The Advacement Of Learning/Mcgill University Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders
US9737512B2 (en) 2015-03-11 2017-08-22 The Board Of Regents Of The University Of Texas System Methods and compositions for treating chronic pain
WO2017097182A1 (fr) * 2015-12-07 2017-06-15 成都海创药业有限公司 Composés de quinoléine, leur procédé de préparation et leur utilisation comme médicament inhibiteur de transporteur d'urate
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
US10722489B2 (en) * 2016-10-31 2020-07-28 Peking University D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof
EP3601274A1 (fr) * 2017-03-31 2020-02-05 Perenna Pharmaceuticals, Inc. Composés utiles en tant qu'inhibiteurs d'alcat 1
WO2018232160A1 (fr) * 2017-06-15 2018-12-20 Belite Bio, Inc Méthodes de traitement de maladies métaboliques avec des phénoxyéthylamides
WO2018232154A1 (fr) 2017-06-15 2018-12-20 Belite Bio, Inc Procédés de traitement de maladies métaboliques avec des pyrazoles bicycliques fusionnés
US10245259B2 (en) 2017-06-15 2019-04-02 Belite Bio, Inc Methods of treating RBP4 related diseases with triazolopyridines
WO2021007172A1 (fr) 2019-07-08 2021-01-14 Belite Bio, Llc Formulations d'inhibiteurs de rbp4 et procédés d'utilisation
JP7360634B2 (ja) 2022-03-23 2023-10-13 いすゞ自動車株式会社 車両制御システム及び荷役制御システム

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999034792A1 (fr) * 1998-01-06 1999-07-15 The General Hospital Corporation Utilisation des inhibiteurs de mek1 comme agents protecteurs contre les lesions consecutives a l'ischemie
WO2002008217A2 (fr) * 2000-07-21 2002-01-31 Chugai Seiyaku Kabushiki Kaisha DERIVES DE LA COUMARINE UTILISES COMME INHIBITEUR DU TNF$g(a)
PT1383756E (pt) * 2001-04-24 2008-06-19 Aryx Therapeutics Derivados de cumarina a utilizar como anticoagulantes
EP1735296B1 (fr) * 2004-04-08 2009-12-09 Aryx Therapeutics Materiaux et procedes de traitement de troubles de la coagulation
US20090253782A1 (en) * 2006-07-18 2009-10-08 Ratan Rajiv R Compounds for Enhancing Arginase Activity and Methods of USe Thereof
KR100821683B1 (ko) * 2006-11-01 2008-04-15 우석대학교 산학협력단 이카리사이드 Ⅱ (ｉｃａｒｉｓｉｄｅ Ⅱ)를 유효성분으로 하는 혈관 형성 장애 관련 질환의 예방 및 치료용 조성물
EP3101017B1 (fr) * 2007-03-20 2019-06-12 Celgene Corporation Dérivés de 4'-o-isoindoline substitués, compositions les comportant et procédés d'utilisation associés
CA2781888C (fr) * 2009-12-11 2019-06-18 Nono Inc. Agents et methodes de traitement de maladies ischemiques et d'autres maladies

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AARTS ET AL., CELL, vol. 115, 2003, pages 863 - 877
AARTS ET AL., SCIENCE, vol. 298, 2002, pages 846 - 850
AARTS; TYMIANSKI, NEUROSCIENTIST, vol. 11, 2005, pages 116 - 123
AARTS; TYMIANSKI, PFLUGERS ARCH., 2005
ALVAREZ ET AL., J. NEUROSCI., vol. 26, 2006, pages 7820 - 7825
See also references of EP2521724A4

Cited By (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9670163B2 (en) 2005-12-28 2017-06-06 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9566284B2 (en) 2009-12-11 2017-02-14 Nono Inc. Agents and methods for treating ischemic and other diseases
EP2578579A1 (fr) * 2010-07-14 2013-04-10 National Institute of Immunology Composés de carboxamide de benzothiophène, compositions et leurs applications
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
US8841487B2 (en) 2010-07-16 2014-09-23 Abbvie Inc. Phosphine ligands for catalytic reactions
US8895737B2 (en) 2010-07-16 2014-11-25 Shashank Shekhar Process for preparing antiviral compounds
US9434698B2 (en) 2010-07-16 2016-09-06 Abbvie Inc. Process for preparing antiviral compounds
US9266913B2 (en) 2010-07-16 2016-02-23 Abbvie Inc. Phosphine ligands for catalytic reactions
US9381508B2 (en) 2010-07-16 2016-07-05 Abbvie Inc. Phosphine ligands for catalytic reactions
US9732045B2 (en) 2010-07-16 2017-08-15 Abbvie Inc. Process for preparing antiviral compounds
US9200021B2 (en) 2010-07-16 2015-12-01 Abbvie Inc. Phosphine ligands for catalytic reactions
US9669399B2 (en) 2010-07-16 2017-06-06 Abbvie Inc. Phosphine ligands for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
US10953007B2 (en) 2010-11-05 2021-03-23 Firmenich Incorporated Compounds useful as modulators of TRPM8
US10016418B2 (en) 2010-11-05 2018-07-10 Seaomyx, Inc. Compounds useful as modulators of TRPM8
US9394287B2 (en) 2010-11-05 2016-07-19 Senomyx, Inc. Compounds useful as modulators of TRPM8
US9334256B2 (en) 2011-06-15 2016-05-10 Nono Inc. Agents and methods for treating ischemic and other diseases
WO2012174488A2 (fr) 2011-06-15 2012-12-20 Nono, Inc. Agents et méthodes de traitement de maladies ischémiques et d'autres maladies
JP2014531402A (ja) * 2011-08-04 2014-11-27 ネオミクス カンパニー リミテッド 新規アニリン誘導体及びこれの用途（Ｎｏｖｅｌａｎｉｌｉｎｅｄｅｒｉｖａｔｉｖｅｓａｎｄｕｓｅｔｈｅｒｅｏｆ）
US9447039B2 (en) 2012-09-07 2016-09-20 Novartis Ag Indole carboxamide derivatives and uses thereof
EP2905278A4 (fr) * 2012-09-28 2016-11-09 Cristália Produtos Químicos Farmacêuticos Ltda Composés hétéroaromatiques, procédé de préparation de ces composé, compositions pharmaceutiques, utilisations et méthode de traitement des douleurs aiguë et chronique
JP2016501192A (ja) * 2012-11-20 2016-01-18 ケイテーベー ツモルフォルシュングスゲゼルシャフト ミット ベシュレンクテル ハフツング プロテインキナーゼ阻害剤としてのチオエーテル誘導体
CN104936963A (zh) * 2012-11-20 2015-09-23 Ktb肿瘤研究有限责任公司 作为蛋白激酶抑制剂的硫醚衍生物
US9925193B2 (en) 2012-11-20 2018-03-27 Proqinase Gmbh Thioether derivatives as protein kinase inhibitors
WO2014079545A1 (fr) * 2012-11-20 2014-05-30 Ktb Tumorforschungsgesellschaft Mbh Dérivés de thioéther utilisés en tant qu'inhibiteurs de protéines kinases
EP2733146A1 (fr) * 2012-11-20 2014-05-21 KTB Tumorforschungsgesellschaft mbH Dérivés de thioéther en tant qu'inhibiteurs de kinase de protéine
US9296755B2 (en) 2013-01-25 2016-03-29 Glaxosmithkline Intellectual Property Development Limited 3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds and their therapeutic applications
US9926333B2 (en) 2013-02-04 2018-03-27 Janssen Pharmaceutica Nv Flap modulators
US9073876B2 (en) 2013-02-04 2015-07-07 Janssen Pharmaceutica Nv Flap modulators
US10047101B2 (en) 2013-02-04 2018-08-14 Janssen Pharmaceautica NV Flap modulators
US9079866B2 (en) 2013-02-04 2015-07-14 Janssen Pharmaceutica Nv Flap modulators
US9884878B2 (en) 2013-02-04 2018-02-06 Janssen Pharmaceutica Nv FLAP modulators
US9745328B2 (en) 2013-02-04 2017-08-29 Janssen Pharmaceutica Nv Flap modulators
WO2014121055A3 (fr) * 2013-02-04 2014-10-02 Janssen Pharmaceutica Nv Modulateurs flap
US9732093B2 (en) 2013-02-04 2017-08-15 Janssen Pharmaceutica Nv FLAP modulators
US9896447B2 (en) 2013-09-22 2018-02-20 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
WO2015039333A1 (fr) * 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions en contenant et procédés correspondants
CN105829297A (zh) * 2013-12-20 2016-08-03 埃斯蒂文博士实验室股份有限公司 具有抗疼痛的多重模式活性的哌啶化合物
EP3705570A1 (fr) 2014-02-10 2020-09-09 Institut Curie Utilisation de modulateurs mcoln-1 afin de réguler la migration cellulaire
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US10975043B2 (en) 2014-10-24 2021-04-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10544111B2 (en) 2014-10-24 2020-01-28 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10214498B2 (en) 2014-10-24 2019-02-26 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2016077793A1 (fr) * 2014-11-14 2016-05-19 Children's Hospital Medical Center Inhibiteurs de sos1 pour le traitement du cancer
US9670205B2 (en) 2015-03-04 2017-06-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10285990B2 (en) 2015-03-04 2019-05-14 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10919902B2 (en) 2015-07-06 2021-02-16 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US11858939B2 (en) 2015-07-06 2024-01-02 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
US9732071B2 (en) 2015-10-01 2017-08-15 Senomyx, Inc. Compounds useful as modulators of TRPM8
US11827609B2 (en) 2016-09-02 2023-11-28 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10370342B2 (en) 2016-09-02 2019-08-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
US11124487B2 (en) 2016-09-02 2021-09-21 Gilead Sciences, Inc. Toll like receptor modulator compounds
CN106565643A (zh) * 2016-10-31 2017-04-19 北京大学 D‑3‑磷酸甘油酸脱氢酶别构抑制剂及其应用
US10793567B2 (en) 2017-01-11 2020-10-06 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10696673B2 (en) 2017-01-11 2020-06-30 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10519149B2 (en) 2017-01-11 2019-12-31 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11225479B2 (en) 2017-01-11 2022-01-18 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US11987580B2 (en) 2017-01-11 2024-05-21 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US11286256B2 (en) 2017-01-11 2022-03-29 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
CN106822897A (zh) * 2017-02-17 2017-06-13 南京九寿堂医药科技有限公司 靶向下调trpm7基因表达在提高肺鳞癌化疗敏感性方面的应用
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11912702B2 (en) 2017-08-07 2024-02-27 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11396509B2 (en) 2019-04-17 2022-07-26 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US11583531B2 (en) 2019-04-17 2023-02-21 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US11286257B2 (en) 2019-06-28 2022-03-29 Gilead Sciences, Inc. Processes for preparing toll-like receptor modulator compounds
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11780840B2 (en) 2020-07-02 2023-10-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022119823A1 (fr) * 2020-12-04 2022-06-09 The Johns Hopkins University Composés et leur utilisation pour le traitement de la douleur neuropathique
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
WO2022148781A1 (fr) 2021-01-05 2022-07-14 Institut Curie Association d'activateurs de mcoln et d'inhibiteurs de point de contrôle immunitaire
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors
CN114685371A (zh) * 2022-03-08 2022-07-01 四川大学 吡唑甲酰胺衍生物及其制备方法和用途
WO2024059524A1 (fr) * 2022-09-12 2024-03-21 Hotspot Therapeutics, Inc. Composés de pyrazolylcarboxamide et leur utilisation en thérapie

Also Published As

Publication number Publication date
AU2010327936A8 (en) 2012-06-28
JP2013513621A (ja) 2013-04-22
US20140235619A1 (en) 2014-08-21
AU2010327936B2 (en) 2015-08-20
US8680137B2 (en) 2014-03-25
CA2781888A1 (fr) 2011-06-16
JP2016117713A (ja) 2016-06-30
JP5848712B2 (ja) 2016-01-27
CA2781888C (fr) 2019-06-18
EP2521724A4 (fr) 2013-11-06
EP2521724A2 (fr) 2012-11-14
JP2018076319A (ja) 2018-05-17
US9566284B2 (en) 2017-02-14
AU2010327936A1 (en) 2012-06-14
US20110251182A1 (en) 2011-10-13
WO2011072275A3 (fr) 2011-12-08
EP2521724B1 (fr) 2016-11-23

Similar Documents

Publication Publication Date Title
CA2781888C (fr) Agents et methodes de traitement de maladies ischemiques et d'autres maladies
da Costa et al. The involvement of the transient receptor potential A1 (TRPA1) in the maintenance of mechanical and cold hyperalgesia in persistent inflammation
Francois et al. State-dependent properties of a new T-type calcium channel blocker enhance CaV3. 2 selectivity and support analgesic effects
Mergler et al. Thermosensitive transient receptor potential channels in human corneal epithelial cells
CA2665490C (fr) Procede pour traiter une degenerescence maculaire
US9334256B2 (en) Agents and methods for treating ischemic and other diseases
Majumdar et al. Na-coupled bicarbonate transporters of the solute carrier 4 family in the nervous system: function, localization, and relevance to neurologic function
US20140336142A1 (en) Method For Treatment Of Macular Degeneration By Modulating P2Y12 or P2X7 Receptors
Kurzen et al. Functional characterization of the epidermal cholinergic system in vitro
Sivakumar et al. Hypoxia-induced retinal ganglion cell damage through activation of AMPA receptors and the neuroprotective effects of DNQX
Calabresi et al. Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study
De Lucchini et al. 5-HT2B-mediated serotonin signaling is required for eye morphogenesis in Xenopus
WO2020214896A1 (fr) Inhibiteurs à petites molécules de rcpg gpr68 et récepteurs associés pour le traitement du cancer, du glioblastome et d'autres indications
Skrzypski et al. Role of TRPV channels in regulating various pancreatic β-cell functions: Lessons from in vitro studies
US20220280473A1 (en) Compositions and methods for modulating epithelial-mesenchymal transition
Ha et al. Molecular Pharmacology Fast Forward. Published on December 6, 2005 as doi: 10.1124/mol. 105.016170
Gasparoli hERG1 channel as a molecular target for new anticancer therapeutic approaches
Soria Cellular role of the putative Ca 2-dependent Cl-channel bestrophin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10836790

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2781888

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010327936

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2012543324

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2010327936

Country of ref document: AU

Date of ref document: 20101210

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2010836790

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010836790

Country of ref document: EP